<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2711234553
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TALTZ 80 mg/ml Injection
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        IXEKIZUMAB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        80
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection in pre-filled pen
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Automatic Injection Device
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        4259.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ELI LILLY" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ELI LILLY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Eli Lilly and Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AC13
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">TALTZ is a prescription medicine used to treat adults:</p><p dir="ltr">&bull;&nbsp; people 6 years of age and older moderate-to-severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet or UV light).</p><p dir="ltr">&bull;&nbsp; adult with active psoriatic arthritis. TALTZ can be used alone or with the medicine methotrexate.</p><p dir="ltr">&bull;&nbsp; adult with active ankylosing spondylitis.</p><p dir="ltr">&bull;&nbsp; with active non-radiographic axial spondyloarthritis with objective signs of inflammation.</p><p dir="ltr">It is not known if TALTZ is safe and effective in children for conditions other than plaque psoriasis or in children under&nbsp;6&nbsp;years of age.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Do not use Taltz</strong></p><p dir="ltr">if you have had a severe allergic reaction to ixekizumab or any of the other ingredients in TALTZ.</p><p dir="ltr">See the end of this leaflet for a complete list of ingredients in TALTZ.</p><p dir="ltr"><strong>Warnings and precautions </strong></p><p dir="ltr">TALTZ is a medicine that affects your immune system. TALTZ may lower the ability of your immune system to fight infections and may increase your risk of infections. Some people have had serious infections while taking TALTZ, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have been hospitalized from these infections.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&bull;&nbsp; Your healthcare provider should check you for TB&nbsp;before you start treatment with TALTZ.</p><p dir="ltr">&bull;&nbsp; Your healthcare provider may treat you with medicine for TB before you begin treatment with TALTZ if you have a past history of TB or have TB.</p><p dir="ltr">&bull;&nbsp; Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with TALTZ.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Before starting TALTZ, tell your healthcare provider if you:</strong></p><p dir="ltr">&bull;&nbsp; are being treated for an infection</p><p dir="ltr">&bull;&nbsp; have an infection that does not go away or that keeps coming back</p><p dir="ltr">&bull;&nbsp; have TB or have been in close contact with someone with TB</p><p dir="ltr">&bull;&nbsp; think you have an infection or have symptoms of an infection such as:</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever, sweats, or chills&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - weight loss</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle aches&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - warm, red, or painful skin or sores on your body</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cough&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - diarrhea or stomach pain</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; - burning when you urinate or urinate more often than normal</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood in your phlegm (mucus)</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>After starting TALTZ, call your healthcare provider right away if you have any of the symptoms of infection listed above.</strong></p><p dir="ltr">Do not use TALTZ if you have any symptoms of infection unless you are instructed to by your healthcare provider.</p><p dir="ltr">See section 4 <strong>&ldquo;Possible side effects&rdquo;</strong> for more information about side effects.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>Before using TALTZ, tell your healthcare provider about all of your medical conditions, including if you:</strong></p><p dir="ltr">&bull;&nbsp; have any of the conditions or symptoms listed above in this section.</p><p dir="ltr">&bull;&nbsp; have Crohn&rsquo;s disease or ulcerative colitis</p><p dir="ltr">&bull;&nbsp; have recently received or are scheduled to receive an immunization (vaccine). You should avoid receiving live vaccines during treatment with TALTZ.</p><p dir="ltr">&bull;&nbsp; are pregnant or plan to become pregnant. It is not known if TALTZ can harm your unborn baby.</p><p dir="ltr">&bull;&nbsp; are breastfeeding or plan to breastfeed. It is not known if TALTZ passes into your breast milk.</p><p dir="ltr">Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>Children and adolescents</strong></p><p dir="ltr">Pediatric psoriasis subjects (6 to less than 18 years of age) were administered ixekizumab at the recommended pediatric dosing regimen for 12 weeks. Subjects weighing &gt;50&nbsp;kg had a mean &plusmn;SD steady-state trough concentration of 3.8 &plusmn;2.2&nbsp;mcg/mL.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>Other medicines and Taltz</strong></p><p dir="ltr">Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.</p><p dir="ltr"><em>Cytochrome P450 Substrates</em></p><p dir="ltr">The formation of CYP450 enzymes can be altered by increased levels of certain cytokines (e.g., IL-1, IL-6, IL-10, TNF&alpha;, IFN) during chronic inflammation. Thus, TALTZ, an antagonist of IL-17A, could normalize the formation of CYP450 enzymes.</p><p dir="ltr">Therefore, upon initiation or discontinuation of TALTZ in patients who are receiving concomitant drugs which are CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for effect (e.g., for warfarin) or drug concentration (e.g., for cyclosporine) and consider dosage modification of the CYP450 substrate.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Pregnancy and breast-feeding </strong></p><p dir="ltr">If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctoror for advice before using this medicine.</p><p dir="ltr">Pregnancy</p><p dir="ltr"><u>Risk Summary</u></p><p dir="ltr">There are no available data on TALTZ use in pregnant women to inform any drug associated risks. Human IgG is known to cross the placental barrier; therefore, TALTZ may be transmitted from the mother to the developing fetus. An embryofetal development study conducted in pregnant monkeys at doses up to 19 times the maximum recommended human dose (MRHD) revealed no evidence of harm to the developing fetus. When dosing was continued until parturition, neonatal deaths were observed at 1.9 times the MRHD <em>[see Data]</em>. The clinical significance of these nonclinical findings is unknown.</p><p dir="ltr">The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</p><p dir="ltr"><u>Data</u></p><p dir="ltr"><em>Animal Data</em></p><p dir="ltr">An embryofetal development study was conducted in cynomolgus monkeys administered ixekizumab. No malformations or embryofetal toxicity were observed in fetuses from pregnant monkeys administered ixekizumab weekly by subcutaneous injection during organogenesis to near parturition at doses up to 19 times the MRHD (on a mg/kg basis of 50&nbsp;mg/kg/week). Ixekizumab crossed the placenta in monkeys.</p><p dir="ltr">In a pre- and post-natal development toxicity study, pregnant cynomolgus monkeys were administered weekly subcutaneous doses of ixekizumab up to 19 times the MRHD from the beginning of organogenesis to parturition. Neonatal deaths occurred in the offspring of two monkeys administered ixekizumab at 1.9 times the MRHD (on a mg/kg basis of 5&nbsp;mg/kg/week) and two monkeys administered ixekizumab at 19 times the MRHD (on a mg/kg basis of 50&nbsp;mg/kg/week). These neonatal deaths were attributed to early delivery, trauma, or congenital defect. The clinical significance of these findings is unknown. No ixekizumab-related effects on functional or immunological development were observed in the infants from birth through 6 months of age.</p><p dir="ltr">Lactation</p><p dir="ltr"><u>Risk Summary</u></p><p dir="ltr">There are no data on the presence of ixekizumab in human milk, the effects on the breastfed infant, or the effects on milk production. Ixekizumab was detected in the milk of lactating cynomolgus monkeys. The developmental and health benefits of breastfeeding should be considered along with the mother&rsquo;s clinical need for TALTZ and any potential adverse effects on the breastfed infant from TALTZ or from the underlying maternal condition.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>See the detailed &ldquo;Instructions for Use&rdquo; that comes with your TALTZ for information on how to prepare and inject a dose of TALTZ, and how to properly throw away (dispose of) used TALTZ autoinjectors.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use TALTZ exactly as prescribed by your or your child&rsquo;s healthcare provider.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For children 6 to 17 years of age:</p><p>o&nbsp;&nbsp; If your child&rsquo;s healthcare provider decides that you may give TALTZ injections at home, you should receive training on the right way to prepare and inject TALTZ. Do not try to give TALTZ to your child until you have been shown how to inject TALTZ.</p><p>o&nbsp;&nbsp; Children should not inject themselves with TALTZ. You or an adult caregiver should prepare and give TALTZ injections to your child.</p><p>o&nbsp;&nbsp; Children will be given a TALTZ injection every 4 weeks.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For adults, if your healthcare provider decides that you or a caregiver may give your TALTZ injections at home, you should receive training on the right way to prepare and inject TALTZ. Do not try to inject TALTZ yourself, until you or your caregiver have been shown how to inject TALTZ.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; TALTZ comes in a single-dose autoinjector hat you or your caregiver may use at home to give injections.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; TALTZ is given as an injection under the skin (subcutaneous injection), in the thighs or stomach area (abdomen) by you or a caregiver. A caregiver may also give the injection of TALTZ in the back of the arm.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do not</strong> give an injection in an area of the skin that is tender, bruised, red or hard, or in an area of skin that is affected by psoriasis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each TALTZ injection should be given at a different site. <strong>Do not</strong> use the 1 inch area around your navel (belly button).</p><p>&nbsp;</p><p><strong>If you or your child forget to take a dose of TALTZ:</strong></p><p>&middot;&nbsp;&nbsp; Do not miss any doses of TALTZ unless your or your child&rsquo;s healthcare provider says it is okay. If you forget to take or give the TALTZ dose, inject a dose as soon as you remember. Then, take or give the next dose at the regular scheduled time.</p><p><strong>&nbsp;</strong></p><p><strong>If you take more TALTZ than you should</strong></p><p>If you inject more TALTZ than prescribed, call your or your child&rsquo;s healthcare provider or go to the nearest emergency room right away.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>TALTZ may cause serious side effects, including:</strong></p><p>&bull;&nbsp; <strong>See section 2 &ldquo;What you need to know before you use TALTZ&rdquo;</strong></p><p>&bull;&nbsp; <strong>Serious allergic reactions.</strong> <strong>If you have a severe allergic reaction, do not give another injection of TALTZ.</strong></p><p>Get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feel faint&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- trouble breathing or throat tightness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of your face, eyelids, lips, mouth, tongue, or throat&nbsp;&nbsp; - chest tightness</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- skin rash</p><p><strong>&bull;&nbsp; Severe skin reactions that look like eczema </strong>can happen<strong> </strong>during treatment with TALTZ from days to months after your first dose and can sometimes lead to hospitalization. Your healthcare provider may temporarily stop treatment with TALTZ if you develop severe skin reactions. Tell your healthcare provider if you have any of the following signs or symptoms:</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>o&nbsp; redness or rash</p><p>o&nbsp; itching</p><p>o&nbsp; patches</p></td><td style="vertical-align:top"><p>o&nbsp; your skin is dry or feels like leather</p><p>o&nbsp; blisters or erosions that ooze or become crusty</p><p>o&nbsp; small bumps or plaques with scale or crusting</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>&bull;&nbsp; Crohn&rsquo;s disease or ulcerative colitis (inflammatory bowel disease) can happen during treatment with TALTZ, including worsening symptoms</strong>. Tell your healthcare provider if you have new or worsening symptoms of inflammatory bowel disease during treatment with TALTZ, including:</p><p>o&nbsp; stomach (abdomen) pain</p><p>o&nbsp; diarrhea with or without blood</p><p>o&nbsp; weight loss</p><p><strong>&nbsp;</strong></p><p><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The most common side effects of TALTZ in adults and children include:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; injection site reaction&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- nausea</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; upper respiratory infections&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - fungal infections</p><p>These are not all of the possible side effects of TALTZ. Tell your healthcare provider about any side effect that bothers you or that does not go away. Call your doctor for medical advice about side effects.</p><p><strong>&nbsp;</strong></p><p><strong>Reporting of side effects</strong><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-font-family:
"Arial Unicode MS";mso-no-proof:yes'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_e409c576-769f-435a-afff-7abd16061cf1 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;mso-fareast-font-family:"Arial Unicode MS";mso-no-proof:yes'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed below. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Keep this medicine out of the sight and reach of children</strong>.</p><p dir="ltr">&bull;&nbsp; Protect TALTZ from light&nbsp;until use.</p><p dir="ltr">&bull;&nbsp; Store TALTZ in the refrigerator between 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F).</p><p dir="ltr">o&nbsp; If needed, you or a caregiver may store TALTZ at room temperature up to 30&deg;C (86&deg;F) for up to 5 days in the original carton to protect from light. Once TALTZ has been stored at room temperature, do not return to the refrigerator. Throw away TALTZ if it is not used within 5 days at room temperature.</p><p dir="ltr">o&nbsp; Record the date when TALTZ is first removed from the refrigerator in the spaces provided on the carton.</p><p dir="ltr">o&nbsp; For the 2 or 3 autoinjector pack, remove a single autoinjector at a time leaving the remaining autoinjector(s) in the original carton in the refrigerator. Ensure the unrefrigerated TALTZ is protected from light.</p><p dir="ltr">&bull;&nbsp; Do not freeze TALTZ. Do not use if TALTZ has been frozen.</p><p dir="ltr">&bull;&nbsp; Do not shake TALTZ.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance(s) is ixekizumab</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are: Polysorbate&nbsp;80, Sucrose, and Water for Injection. Sodium Hydroxide may have been added to adjust pH.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                TALTZ is a clear and colorless to slightly yellow solution available as:
Autoinjector
•	Injection: 80 mg/mL solution of TALTZ in a single-dose prefilled autoinjector
General information about the safe and effective use of TALTZ.
	Medicines are sometimes prescribed for purposes other than those listed in the patient leaflet. Do not use TALTZ for a condition for which it was not prescribed. Do not give TALTZ to other people, even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for information about TALTZ that is written for health professionals.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Marketing Authorization Holder:</p><p dir="ltr">Eli Lilly and Company, Indianapolis, IN 46285, USA</p><p dir="ltr">&nbsp;</p><p dir="ltr">Manufacturer and Packaging site:</p><p dir="ltr">Eli Lilly and Company, Lilly Corporate Center. Indianapolis, Indiana (IN) 46285, USA.</p><p dir="ltr">&nbsp;</p><p dir="ltr">For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p dir="ltr">Eli Lilly &amp; Company &ndash; Saudi Arabia</p><p dir="ltr">PO Box 92120</p><p dir="ltr">16th Floor, Building Number 3074,</p><p dir="ltr">Tower B, Olaya Towers</p><p dir="ltr">Prince Mohamed Ibn Abdulaziz Street</p><p dir="ltr">Olaya, Riyadh</p><p dir="ltr">Kingdom of Saudi Arabia</p><p dir="ltr">Direct Line:&nbsp; +966 11 461 7800, +966 11 4617850&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="ltr">Fax: +966 11 217 9900</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                August 2024
Version 7

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">تالتز هو دواء يوصف بوصفة طبيّة يُستخدم لعلاج البالغين المصابين بأحد الأمراض التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المرضى من سن ٦ سنوات فما أكثر، المصابين بالصدفيّة اللويحية المتوسّطة إلى الشديدة، الذين قد يستفيدون من أخذ الحقن أو الأقراص (العلاج الشامل) أو المعالجة بالضوء (العلاج باستخدام الأشعة فوق البنفسجية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البالغين المصابين بالتهاب المفاصل الصدفي النشط. يمكن استخدام تالتز بمفرده أو مع دواء ميثوتريكسات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البالغين المصابين بالتهاب الفقرات الروماتويديّ النشط. &nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المفاصل الفقاري المحوري غير الإشعاعي النشط، مع علامات التهاب موضوعية. &nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">من غير المعروف ما إذا كان تالتز آمنًا وفعالًا للاستخدام لدى الأطفال المصابين بأمراض أخرى غير الصدفيّة اللويحية أو البالغين من العمر أقل من ٦ سنوات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>عليك الامتناع عن استخدام تالتز</strong></p><p dir="RTL">إذا كنت قد عانيت من تفاعل تحسّسي شديد تجاه الإيكسيكيزوماب أو أي من المكوّنات الأخرى لتالتز.</p><p dir="RTL">راجع الجزء الأخير من هذه النشرة للاطّلاع على القائمة الكاملة لمكوّنات تالتز.&nbsp;&nbsp; &nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات &nbsp;</strong></p><p dir="RTL">تالتز من الأدوية التي تؤثر على جهازك المناعي. قد يخفض تالتز قدرة الجهاز المناعي على محاربة العدوى، كما أنّه قد يزيد من خطر الإصابة بالعدوى، ما يُمكن أن يتّسم بالخطورة في بعض الحالات. أصيب بعض الأشخاص بعدوى خطيرة أثناء تناولهم دواء تالتز، بما في ذلك مرض السلّ، وحالات عدوى ناجمة عن البكتيريا أو الفطريّات أو الفيروسات التي يمكن أن تنتشر في جميع أنحاء الجسم. وقد نُقِلَ بعض الأشخاص إلى المستشفى بسبب حالات العدوى هذه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; على أخصائي الرعاية الصحية أن يتّأكّد من عدم إصابتك بالسلّ قبل أن تبدأ العلاج بتالتز.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يعالجك أخصائي الرعاية الصحية بدواء للسلّ قبل أن تبدأ العلاج بتالتز إذا كنت مصابًا بالسلّ أو سبق لك أن أُصبت بهذا المرض.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; على أخصائي الرعاية الصحية أن يُخضعك للمراقبة عن كثب لرصد علامات وأعراض الإصابة بالسلّ أثناء العلاج بتالتز وبعده. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قبل بدء العلاج بتالتز، عليك إطلاع أخصائي الرعاية الصحية على ما يلي: </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتلقّى علاجًا لعدوى معيّنة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بعدوى دائمة أو متكرّرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالسلّ أو إذا احتككت بشخص مصاب بالسلّ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعتقد بأنّك مصابٌ بعدوى أو تظهر عليك أعراض عدوى من مثل:</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمّى، التعرّق أو القشعريرة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام العضلات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السُعال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;ضيق التنفس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود دم في البلغم (البُصاق)</p></td><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سخونة، احمرار أو ألم على مستوى الجلد، أو تقرّحات في الجسم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال أو آلام المعدة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحرقان أثناء التبوّل أو التبوّل المفرط</p></td></tr></tbody></table><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>بعد البدء باستخدام تالتز، يتعيّن عليك الاتصال</strong><strong> بأخصائي الرعاية الصحية على الفور إذا ظهرت عليك أيّ من أعراض العدوى المذكورة أعلاه.</strong></p><p dir="RTL">عليك الامتناع عن استخدام تالتز إذا كانت لديك أيّ من أعراض العدوى، ما لَم يطلب منك ذلك أخصائي الرعاية الصحية.</p><p dir="RTL">راجع القسم ٤ <strong>&quot;الآثار الجانبية المحتملة&quot;</strong> لمزيد من المعلومات حول الآثار الجانبية. &nbsp;</p><p dir="RTL">&nbsp;&nbsp;</p><p dir="RTL"><strong>قبل البدء باستخدام تالتز، عليك إطلاع </strong><strong>أخصائي الرعاية الصحية على أيّ ظروف صحية قد تعاني منها، بما في ذلك: &nbsp;</strong><strong>&nbsp;</strong><strong>&nbsp;</strong><strong>&nbsp;&nbsp;&nbsp;</strong><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أيّ من الحالات أو الأعراض الواردة سابقا في هذه الفقرة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بداء كرون أو بالتهاب القولون التقرّحي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد تلقّيت مؤخرًا أو من المقرّر أن تتلقّى تمنيعًا (لقاحًا) في وقت قريب. عليك تجنب تلقي اللقاحات الحية أثناء العلاج بتالتز.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملًا أو تخطّطين للإنجاب. من غير المعروف ما إذا كان تالتز قد يُضرّ بالجنين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ مرضعة أو تخطّطين للإرضاع. من غير المعروف ما إذا كان تالتز ينتقل إلى حليب الأم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عليك إطلاع أخصائي الرعاية الصحية على جميع الأدوية التي تتناولها، بما فيها الأدوية الموصوفة لك وتلك المتاحة بدون وصفة طبية، والفيتامينات والمكمّلات العشبيّة. &nbsp;&nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">تم إعطاء إيكسيكيزوماب لمرضى الصدفية من الأطفال (من عمر ٦ إلى أقل من ١٨ عامًا) في نظام جرعات الأطفال الموصى به لمدة ١٢ أسبوعًا. المرضى الذين يزيد وزنهم عن ٥٠ كلغم كان ​​تركيز الدواء في الحالة الثابتة&nbsp; يبلغ ٣.٨ &plusmn; ٢.٢ ميكروغرام / مل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تالتز والأدوية الأخرى</strong></p><p dir="RTL">عليك إطلاع الطبيب أو الصيدلي إذا كنت تستخدم أدوية أخرى، أو إذا كنت قد استخدمت أدوية أخرى في الفترة الأخيرة أو يمكن أن تستخدمها في وقت قريب.</p><p dir="RTL"><em>المواد المتأثرة بأنزيمات سيتوكروم ٤٥٠</em><em>p</em><em> </em><em>)</em> <em>٤٥٠</em><em>CYP</em><em>)</em></p><p dir="RTL">يُمكن أن يتأثّر تشكّل أنزيمات ٤٥٠CYP بتزايد مستويات بعض السيتوكينات (من مثل ١IL-، ٦IL-، ١٠IL-،TNF&alpha; وIFN) في حالات الالتهابات المزمنة. وبالتالي فإنّ تالتز، المضاد لسيتوكين A ١٧IL-، يمكن أن يعيد عمليّة تشكّل أنزيمات ٤٥٠CYP إلى وضعها الطبيعي.</p><p dir="RTL">لذا، عند بدء أو إيقاف العلاج بتالتز لدى المرضى الذين يتلقّون في الوقت عينه أدوية تُعدّ من المواد المتأثرة بأنزيمات سيتوكروم ٤٥٠p، لا سيّما تلك ذات المنسب العلاجي الضيّق، ينبغي رصد التأثير (للوارفارين، على سبيل المثال) أو تركيز الدواء (للسيكلوسبورين، على سبيل المثال)، كما ينبغي النظر في الحاجة إلى تعديل جرعة المادة المتأثرة بأنزيمات ٤٥٠CYP.&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل والإرضاع </strong></p><p dir="RTL">إذا كنتِ حاملًا أو مرضعة، أو تشكّين بأنّك حامل أو تخطّطين للإنجاب، استشيري طبيبك قبل أخذ هذا الدواء.</p><p dir="RTL">الحمل</p><p dir="RTL"><u>موجز المخاطر</u></p><p dir="RTL">لا تتوافر أيّ بيانات حول استخدام تالتز لدى النساء الحوامل لتوثيق أي مخاطر مرتبطة بهذا الدواء. من المعروف أنّ الغلوبولين المناعي ج (IgG) لدى الإنسان يعبر الحاجز المشيمي؛ وبالتالي فإنّ تالتز قد ينتقل من الأم إلى الجنين النامي. ولم تكشف دراسة لنموّ الأجنّة أجريت على قردة حوامل أيّ مؤشرات على لحاق ضرر بالأجنّة النامية بعد تلقّي القردة جرعات تصل إلى ١٩ ضعف الجرعة القصوى الموصى بها للإنسان. عند الاستمرار في إعطاء الدواء حتّى الولادة، سُجّلت حالات وفاة وليدية بعد تلقّي جرعات تبلغ ١.٩ أضعاف الجرعة القصوى الموصى بها للإنسان [انظر فقرة &quot;البيانات&quot;]. إنّ الأهمية السريرية لهذه النتائج غير السريرية غير معروفة.</p><p dir="RTL">كما أنّ الخطر الطبيعي لحدوث العيوب الخلقية الكبرى والإجهاض في الفئة المشار إليها غير معروف. على مستوى سكّان الولايات المتحدة بشكل عام، يُقدّر الخطر الطبيعي لحدوث العيوب الخلقية الكبرى والإجهاض في حالات الحمل المعترف بها سريريًا بنسبة ٢ إلى ٤٪ و١٥ إلى ٢٠٪، على التوالي.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL"><u>البيانات</u></p><p dir="RTL">البيانات الحيوانية</p><p dir="RTL">أجريت دراسة لنموّ الأجنّة على قردة من نوع المكاك الطويل الذيل تمّ إعطاؤها مادة إيكسيكيزوماب. لم تُسجّل أي تشوّهات أو سميّة جنينيّة لدى أجنّة القردة الحوامل التي تلقّت إيكسيكيزوماب أسبوعيًا عن طريق الحقن تحت الجلد خلال مرحلة تكوّن الأعضاء وحتّى اقتراب موعد الولادة، بجرعات تصل إلى ١٩ ضعف الجرعة القصوى الموصى بها للإنسان (على أساس ٥٠ ملغ/كلغ/أسبوع). جدير بالذكر أنّ الإيكسيكيزوماب عَبَر المشيمة لدى القردة.</p><p dir="RTL">وفي إطار دراسة للسميّة على النموّ ما قبل الولادة وما بعدها، أعطيت قردة حوامل من نوع المكاك الطويل الذيل حقن أسبوعيّة تحت الجلد من الإيكسيكيزوماب بجرعات تصل إلى ١٩ ضعف الجرعة القصوى الموصى بها للإنسان منذ بداية مرحلة تكوّن الأعضاء وحتّى موعد الولادة. سُجّلت حالات وفاة وليديّة لدى مواليد اثنتين من القردة التي أعطيت الإيكسيكيزوماب بجرعة تبلغ ١.٩ أضعاف الجرعة القصوى الموصى بها للإنسان (على أساس ٥ ملغ/كلغ/أسبوع)، واثنتين من القردة التي أعطيت الإيكسيكيزوماب بجرعة تبلغ ١٩ ضعف الجرعة القصوى الموصى بها للإنسان (على أساس ٥٠ ملغ/كلغ/أسبوع). وقد عُزيت هذه الوفيّات الوليديّة إلى الولادة المبكرة أو الصدمة أو العيوب الخلقيّة. لكنّ الأهمية السريرية لهذه النتائج غير معروفة. ولم تُلاحظ أيّ آثار مرتبطة بالإيكسيكيزوماب على النموّ الوظيفي أو نموّ الجهاز المناعي لدى المواليد من الولادة وخلال الأشهر الستة الأولى من حياتها.&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">الإرضاع</p><p dir="RTL"><u>موجز المخاطر</u></p><p dir="RTL">لا بيانات عن وجود آثار للإيكسيكيزوماب في الحليب البشري، أو عن تأثيره على الوليد الذي يتمّ إرضاعه طبيعيًا أو تأثيره على إدرار الحليب. لكن تمّ الكشف عن وجود آثار للإيكسيكيزوماب في حليب القرَدة المُرضعة من نوع المكاك الطويل الذيل. وينبغي في هذا الإطار مراعاة فوائد الإرضاع على النمو والصحة، إلى جانب حاجة الأمّ السريرية لتلقّي تالتز وأي آثار سلبيّة محتملة لهذا الدواء أو لحالة الأم الأساسيّة على الوليد الذي يتمّ إرضاعه طبيعيًا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ينبغي استخدام هذا الدواء دائمًا بحسب التعليمات الدقيقة للطبيب أو الصيدلي. وإذا لم تكن متأكّدًا، عليك استشارة طبيبك أو الصيدلي.</p><p dir="RTL"><strong>راجع &quot;دليل الاستخدام&quot; المفصّل المرفق </strong><strong>بدواء تالتز للاطّلاع على كيفيّة إعداد وحقن جرعة من تالتز، وكيفيّة</strong><strong> </strong><strong>التخلّص من أجهزة حقن تالتز الذاتي التي سبق استعمالها. &nbsp;&nbsp;</strong><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استخدم دواء تالتز تماماً كما وصفه لك مقدّم الرعاية الصحيّة الذي يتابعك أو يتابع طفلك. للأطفال بين 6 و17 عامًا من العمر:</p><p dir="RTL">-&nbsp; إذا قرّر مقدّم الرعاية الصحيّة الذي يتابع طفلك أنه يمكنك إعطاء حقن تالتز في المنزل، فيجب أن تتلقى تدريبًا على الطريقة الصحيحة لتحضير تالتز وحقنه. لا تحاول إعطاء تالتز لطفلك حتى يتمّ تعليمك كيفيّة حقن تالتز.</p><p dir="RTL">-&nbsp; يجب ألا يحقن الأطفال أنفسهم بدواء تالتز. يجب أن تقوم أنت أو مقدّم رعاية بالغ بتحضير حقن تالتز وإعطائها لطفلك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيتم إعطاء الأطفال حقنة تالتز كلّ 4 أسابيع. بالنسبة للبالغين، إذا ارتأى أخصائي الرعاية الصحية أنّك قادرٌ على أخذ حقن تالتز بنفسك أو أنّ مقدّم الرعاية الخاص بك قادر على إعطائك إياها في المنزل، ينبغي أن يتمّ تدريبكما على الطريقة الصحيحة لإعداد وحقن تالتز. لا تحاول أن تأخذ حقنة تالتز بنفسك إلّا بعد أن تتعلّم أو أن يتعلّم مقدّم الرعاية كيفية حقن تالتز.</p><p dir="RTL">-&nbsp; يأتي تالتز على شكل جهاز حقن ذاتي من جرعة واحدة ، وبإمكانك استخدامه، أو الاستعانة بمقدّم الرعاية لإعطائك إياه في المنزل.</p><p dir="RTL">يُعطى تالتز عن طريق الحقن تحت الجلد، في الفخذين أو في منطقة البطن، وبإمكانك أخذ الحقنة بنفسك أو الاستعانة بمقدّم الرعاية الصحية، كما يُمكن لهذا الأخير إعطاء الحقنة من تالتز في المنطقة الخلفيّة من الذّراع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي <strong>الامتناع</strong> عن الحقن في الأجزاء المؤلمة أو حيث تظهر على البشرة آثار كدمات أو احمرار أو الأجزاء الصلبة، وكذلك في أيّ منطقة من الجلد مصابة بالصدفية.&nbsp; &nbsp;&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي إعطاء كلّ حقنة من تالتز في موضع مختلف عن الحقنة السابقة، كما يوصى <strong>بالامتناع</strong> عن الحقن ضمن مسافة بوصة من السرّة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا نسيت أنت أو طفلك أخذ جرعة من تالتز</strong><strong> </strong></p><p dir="RTL">لا تفوّت أيّ جرعة من تالتز إلّا إذا اعتبر أخصائي الرعاية الصحية الذي يتابعك أو مقدّم الرعاية الصحيّة الذي يتابع طفلك بأنّ لا بأس في ذلك. إذا نسيت أن تأخذ جرعتك من تالتز أو إعطاءها في الوقت المحدد ، خذ الحقنة ما إن تتذكّر، ثمّ، خذ جرعتك التالية أو أعطها في الوقت المحدد المعتاد لها.&nbsp;&nbsp;&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا حقنت جرعة من تالتز أكبر&nbsp; مما تحتاج</strong></p><p dir="RTL">إذا حقنت نفسك بكميّة من تالتز تفوق الكمية الموصوفة لك، اتّصل بأخصائي الرعاية الصحية الذي يتابعك أو مقدّم الرعاية الصحيّة الذي يتابع طفلك أو توجّه مباشرة إلى أقرب قسم طوارئ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أيّ أسئلة إضافية حول استخدام هذا الدواء، اسأل الطبيب أو الصيدليّ أو الممرّض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">على غرار جميع الأدوية، قد يسبّب هذا الدواء آثارًا جانبية، وإن لم تكن تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد يُسبّب تالتز آثارًا جانبية خطيرة، بما في ذلك: </strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>راجع القسم</strong><strong> </strong><strong>٢</strong><strong> </strong><strong>&quot;</strong><strong>ما ينبغي معرفته قبل البدء باستخدام تالتز</strong><strong>&quot;</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>التفاعلات التحسسية الخطيرة. إذا أصبت بتفاعل تحسّسي شديد، لا تأخذ حقنة ثانية من تالتز. </strong></p><p dir="RTL">احصل على مساعدة طبية طارئة على الفور إذا عانيت من أيّ من الأعراض التالية التي تشير إلى تفاعل تحسّسي خطير:</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp; الشعور بالوهن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; تورّم الوجه، الجفون، الشفاه، الفم، اللسان أو الحلق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; الطفح الجلدي</p></td><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp; صعوبة في التنفّس أو ضيق في الحلق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; ضيق الصّدر</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>يمكن أن تحدث تفاعلات جلديّة شديدة تشبه الأكزيما </strong>أثناء العلاج بدواء تالتز من أيّام إلى أشهر بعد الجرعة الأولى وقد تؤدي بعض الأحيان إلى دخول المستشفى. قد يقوم مقدم الرعاية الصحيّة الذي يتابعك بإيقاف العلاج بدواء تالتز مؤقتًا إذا أصبت بردود فعل جلديّة حادة. أخبر مقدم الرعاية الصحيّة الذي يتابعك إذا كان لديك أيّ من العلامات أو الأعراض التالية:</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp; بشرتك جافة أو تبدو مدبوغ جلد</p></td><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp; احمرار أو طفح جلدي&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp; بثور أو تقرّحات تنزّ أو تصبح قشريّة&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp; حكّة&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp; نتوءات أو لويحات الصغيرة ذات قشور أو تقشّر&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp; بقع على الجلد</p></td></tr></tbody></table><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>قد يُصاب المريض بداء كرون أو &nbsp;بالتهاب القولون التقرّحي (داء الأمعاء الالتهابي) أثناء العلاج بتالتز، بما في ذلك تفاقم الأعراض.</strong> عليك إطلاع أخصائي الرعاية الصحية إذا عانيت من أعراض جديدة أو متفاقمة لداء الأمعاء الالتهابي أثناء تلقّيك العلاج بتالتز، بما في ذلك:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام في المعدة (البطن)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال، مع أو بدون دم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>وتشمل الآثار الجانبية الأكثر شيوعًا لتالتزلدى البالغين و الأطفال: </strong></p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التفاعل في موضع الحقن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجهاز التنفسي العلوي</p></td><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى الفطرية</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">هذه ليست كل الآثار الجانبية المحتملة لتالتز. أخبر أخصائي الرعاية الصحية عن أيّ آثار جانبية تُزعجك أو تستمرّ. اتّصل بطبيبك للحصول على مشورة طبية بشأن الآثار الجانبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبيّة</strong></p><p dir="RTL">إذا شعرت بأيّ آثار جانبية، عليك التحدّث مع الطبيب أو الصيدلي أو الممرّض. ويشمل هذا أيّ آثار جانبية محتملة غير مدرجة في هذه النشرة. كما يمكنك الإبلاغ عن الآثار الجانبية مباشرة عن طريق نظام الإبلاغ الوطني المشار إليه أدناه. من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساهمة في توفير مزيد من المعلومات حول سلامة هذا الدواء.&nbsp;&nbsp;&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يُحفظ هذا الدواء بعيدًا عن مرأى الأطفال ومتناولهم</strong><strong>.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي حماية تالتز من الضوء&nbsp;حتى وقت الاستخدام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُخزّن تالتز في الثلاجة في درجة حرارة تتراوح بين ٢ و٨ درجات مئوية (٣٦ و٤٦ درجة فهرنهايت).&nbsp; &nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لزم الأمر، بإمكان المريض أو مقدّم الرعاية الصحية تخزين تالتز في درجة حرارة الغرفة على ألّا تزيد عن ٣٠ درجة مئوية (٨٦ درجة فهرنهايت) لمدّة تصل إلى ٥ أيام، داخل علبته الأصلية لحمايته من الضوء. بعد تخزين تالتز في درجة حرارة الغرفة، ينبغي الامتناع عن إعادته إلى الثلاجة والتخلّص منه في حال عدم استعماله في غضون ٥ أيام.&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يوصى بتسجيل تاريخ إخراج تالتز من الثلاجة في المكان المخصص لذلك على العلبة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالنسبة إلى الحزمة التي تضمّ جهازين ذاتيين للحقن أو ثلاثة، ينبغي إخراج جهاز واحد من العلبة في كلّ مرّة وترك البقية في العلبة الأصلية داخل الثلاجة. من الضروري الحرص على حماية أجهزة حقن تالتز الموجودة خارج الثلاجة من الضوء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كما ينبغي الامتناع عن تجميد تالتز وعدم استخدامه في حال كان قد تجمّد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ويوصى كذلك بالامتناع عن رجّ تالتز.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي الامتناع عن رمي أيّ أدوية في مياه الصرف الصحي أو مع النفايات المنزلية، واستشارة الصيدلي حول كيفية التخلّص من الأدوية التي توقّفت عن استخدامها. من شأن هذه التدابير المساهمة في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مكوّنات تالتز</strong><strong> </strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp; المادة الفعالة هي الإيكسيكيزوماب &nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; المكوّنات الأخرى هي: البوليسوربات ٨٠سكروز، &nbsp;والماء للحقن.</p><p dir="RTL">ويُمكن أن يكون هيدروكسيد الصوديوم قد استُخدم لضبط الحموضة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تالتز محلول صافٍ وعديم اللون إلى مصفرّ قليلًا، وهو متوفر على شكل:</p><p dir="RTL">جهاز حقن ذاتي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حقنة: ٨٠ ملغ/مل من تالتز في جهاز حقن ذاتي أحادي الجرعة مسبق التعبئة&nbsp;</p><p dir="RTL"><strong>معلومات عامة حول الاستخدام الآمن والفعّال لتالتز.&nbsp; </strong></p><p dir="RTL">توصف الأدوية أحيانًا لأغراض غير تلك المذكورة في نشرة المريض. يوصى بالامتناع عن استخدام تالتز للحالات التي لم يوصف لها. كما ينبغي الامتناع عن إعطاء تالتز للآخرين، حتّى وإن كانوا يعانون من أعراض مشابهة لأعراضك، لأنّه قد يؤذيهم. يُمكنك أن تطلب من أخصائي الرعاية الصحية أو من الصيدلي معلومات عن تالتز موجّهة إلى المهنيّين الصحيين.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">حامل رخصة التسويق:</p><p dir="RTL">شركة إيلي ليلي وشركاه. إنديانابوليس، ولاية إنديانا ٤٦٢٨٥، الولايات المتّحدة</p><p dir="RTL">&nbsp;</p><p dir="RTL">المصنّع وموقع التغليف:</p><p dir="RTL">شركة إيلي ليلي وشركاه. مركز الشركة ليلي. إنديانابوليس، ولاية إنديانا ٤٦٢٨٥. الولايات المتّحدة الأمريكية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">للحصول على أيّ معلومات تتعلّق بهذا الدواء، يُرجى الاتصال بالممثل المحلّي لحامل رخصة التسويق:</p><p dir="RTL">إيلي ليلي وشركاه - المملكة العربية السعودية</p><p dir="RTL">صندوق البريد ٩٢١٢٠</p><p dir="RTL">الطابق ١٦، رقم المبنى ٣٠٧٤</p><p dir="RTL">البرج B، أبراج العليا</p><p dir="RTL">شارع الأمير محمد بن عبد العزيز</p><p dir="RTL">العليا، الرياض</p><p dir="RTL">المملكة العربية السعودية</p><p dir="RTL">الخط المباشر: ٩٦٦١١٤٦١٧٨٠٠+، ٩٦٦١١٤٦١٧٨٥٠ &nbsp;&nbsp;&nbsp;+&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">فاكس: ٩٦٦١١٢١٧٩٩٠٠+</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أغسطس 2024
	النسخة 8 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Taltz 80mg/ml, solution in a single-dose prefilled autoinjector.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
2.1	General description

Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) with neutralizing activity against IL-17A. Ixekizumab is produced by recombinant DNA technology in a recombinant mammalian cell line and purified using standard technology for bioprocessing. Ixekizumab is comprised of two identical light chain polypeptides of 219 amino acids each and two identical heavy chain polypeptides of 445 amino acids each, and has a molecular weight of 146,158 Daltons for the protein backbone of the molecule.

TALTZ injection is a sterile, preservative free, clear and colorless to slightly yellow solution, for subcutaneous use available as 80 mg of ixekizumab in a 1 mL single-dose prefilled autoinjector. The prefilled autoinjector contains a 1 mL glass syringe with a fixed 27 gauge ½ inch needle. The TALTZ 80 mg prefilled autoinjector is manufactured to deliver 80 mg of ixekizumab.

2.2	Qualitative and quantitative composition

Each mL is composed of ixekizumab (80 mg); Each mL is composed of ixekizumab (80 mg); Polysorbate 80, USP (0.3 mg); Sucrose, USP (80 mg); and Water for Injection, USP. Sodium Hydroxide, USP-NF, may have been added to adjust pH. The TALTZ solution has a pH of 5. 2 – 6.2.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                TALTZ is a clear and colorless to slightly yellow solution available as:
Autoinjector
•	Injection: 80 mg/mL solution of TALTZ in a single-dose prefilled autoinjector

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Plaque Psoriasis</p><p dir="ltr">TALTZ is indicated for the treatment of patients 6 years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Psoriatic Arthritis</p><p dir="ltr">TALTZ is indicated for the treatment of adult patients with active psoriatic arthritis.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ankylosing Spondylitis</p><p dir="ltr">TALTZ is indicated for the treatment of adult patients with active ankylosing spondylitis.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-radiographic Axial Spondyloarthritis</p><p dir="ltr">TALTZ is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Testing and Procedures Prior to Treatment Initiation</strong></p><p>Perform the following evaluations prior to TALTZ initiation:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Evaluate patients for tuberculosis (TB) infection. TALTZ initiation is not recommended in patients with active TB infection. Initiate treatment of latent TB prior to initiation of TALTZ <em>[see Special warnings and precautions for use (4.4)]</em>.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Complete all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating treatment with TALTZ <em>[see Special warnings and precautions for use (4.4)]</em>.</p><p>&nbsp;</p><p dir="ltr"><strong>Recommended Dosage in</strong> <strong>Adult Plaque Psoriasis</strong></p><p dir="ltr">TALTZ is administered by subcutaneous injection. The recommended dosage in adults with moderate-to-severe plaque psoriasis is 160&nbsp;mg (two 80&nbsp;mg injections) at Week 0, followed by 80&nbsp;mg at Weeks 2, 4, 6, 8, 10, and 12, then 80&nbsp;mg every 4 weeks.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>Recommended Dosage in Pediatric Plaque Psoriasis</strong></p><p dir="ltr">TALTZ is administered by subcutaneous injection every 4 weeks (Q4W). The recommended dosage&nbsp;in pediatric patients from 6 to less than 18 years of age with moderate-to-severe plaque psoriasis that are greater than 50 kg is 160&nbsp;mg by subcutaneous injection (two 80&nbsp;mg injections) at week 0, followed by 80&nbsp;mg every 4 weeks.</p><p dir="ltr"><strong>Recommended Dosage in Psoriatic Arthritis</strong></p><p dir="ltr">The recommended dosage&nbsp;is 160&nbsp;mg by subcutaneous injection (two 80&nbsp;mg injections) at week 0, followed by 80&nbsp;mg every 4 weeks.</p><p dir="ltr">For psoriatic arthritis patients with coexistent moderate-to-severe plaque psoriasis, use the dosing regimen for adult plaque psoriasis<em>.</em></p><p dir="ltr">TALTZ may be administered alone or in combination with a conventional disease-modifying antirheumatic drug (cDMARD) (e.g., methotrexate).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Recommended Dosage in Ankylosing Spondylitis</strong></p><p dir="ltr">The recommended dosage&nbsp;is 160&nbsp;mg by subcutaneous injection (two 80&nbsp;mg injections) at Week 0, followed by 80&nbsp;mg every 4 weeks.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Recommended Dosage in Non-radiographic Axial Spondyloarthritis</strong></p><p dir="ltr">The recommended dosage&nbsp;is 80&nbsp;mg by subcutaneous injection every 4 weeks.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>Preparation and Administration Instructions</strong></p><p dir="ltr">TALTZ is intended for use under the guidance and supervision of a healthcare provider.. Adult patients may self-inject or caregivers may give injections of TALTZ&nbsp;after training in subcutaneous injection technique using the autoinjector. Safety and effectiveness of pediatric self-administration has not been established. Therefore, TALTZ should be administered to pediatric patients by a healthcare provider or by a caregiver who has received &nbsp;training and demonstrated proper subcutaneous injection technique.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The TALTZ &ldquo;Instructions for Use&rdquo; contains more detailed instructions on the preparation and administration of TALTZ <em>[see Instructions for Use]</em>.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Before injection, remove TALTZ autoinjector or from the refrigerator and allow TALTZ to reach room temperature (30&nbsp;minutes) without removing the needle cap. Inspect TALTZ visually for particulate matter and discoloration prior to administration. TALTZ is a clear and colorless to slightly yellow solution. Do not use if the liquid contains visible particles, is discolored or cloudy (other than clear and colorless to slightly yellow).</p><p dir="ltr">Administer each injection at a different anatomic location (such as upper arms, thighs or any quadrant of abdomen) than the previous injection, and not into areas where the skin is tender, bruised, erythematous, indurated or affected by psoriasis. Administration of TALTZ in the upper, outer arm may be performed by a caregiver or healthcare provider <em>[see Instructions for Use]</em>.</p><p dir="ltr">TALTZ does not contain preservatives, therefore discard any unused product.</p><p dir="ltr">If a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing at the regular scheduled time.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                TALTZ is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients [see Special warnings and precautions for use (4.4)].
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Infections</strong></p><p dir="ltr">TALTZ may increase the risk of infection. In clinical trials in adult patients with plaque psoriasis, the TALTZ group had a higher rate of infections than the placebo group (27% vs. 23%). Upper respiratory tract infections, oral candidiasis, conjunctivitis and tinea infections occurred more frequently in the TALTZ group than in the placebo group. A similar increase in risk of infection was seen in placebo- controlled trials in patients with pediatric psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis <em>[see Undesirable Effects (4.8)].</em>&nbsp;In the postmarketing setting, serious bacterial, viral, and fungal opportunistic infections have been reported in patients receiving IL-17 inhibitors including TALTZ.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Instruct patients treated with TALTZ to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a serious infection or is not responding to standard therapy, monitor the patient closely and discontinue TALTZ until the infection resolves.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Pre-treatment Evaluation for Tuberculosis</strong></p><p dir="ltr">Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with TALTZ. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering TALTZ. Consider anti-TB therapy prior to initiating TALTZ in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Patients receiving TALTZ should be monitored closely for signs and symptoms of active TB during and after treatment.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Hypersensitivity</strong></p><p dir="ltr">Serious hypersensitivity reactions, including angioedema and urticaria (each &le;0.1%), occurred in the TALTZ group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in post marketing use with TALTZ <em>[see Undesirable Effects (4.8)]</em>. If a serious hypersensitivity reaction occurs, discontinue TALTZ immediately and initiate appropriate therapy.</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p><p><strong>Eczematous Eruptions</strong></p><p>In the postmarketing setting, cases of severe eczematous eruptions, including atopic dermatitis-like eruptions, dyshidrotic eczema, and erythroderma were reported in patients receiving TALTZ; some cases resulted in hospitalization. The onset of eczematous eruptions was variable, ranging from days to months after the first dose of TALTZ. Treatment may need to be discontinued to resolve the eczematous eruption. Some patients with limited psoriasis treatment options were successfully treated for eczema while continuing TALTZ.</p><p dir="ltr"><strong>Inflammatory Bowel Disease</strong></p><p dir="ltr">Patients treated with TALTZ may be at increased risk of inflammatory bowel disease. In clinical trials, Crohn&rsquo;s disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the TALTZ group &nbsp;than the placebo control group <em>[see undesirable effects (4.8)].</em> During TALTZ treatment, monitor for onset or exacerbation of inflammatory bowel disease and if IBD occurs, discontinue TALTZ and initiate appropriate medical management.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Immunizations</strong></p><p dir="ltr">Prior to initiating therapy with TALTZ, consider completion of all age appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TALTZ. No data are available on the response to live vaccines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In plaque psoriasis studies, the safety of Taltz in combination with other immunomodulatory agents or phototherapy has not been evaluated.</p><p>In population pharmacokinetic analyses, clearance of ixekizumab was not affected by concomitant administration of oral corticosteroids, NSAIDs, sulfasalazine, or methotrexate.</p><p>&nbsp;</p><p><u>Cytochrome P450 substrates</u></p><p>Results from an interaction study in patients with moderate-to-severe psoriasis determined that 12&nbsp;weeks of administration of ixekizumab with substances metabolised by CYP3A4 (i.e., midazolam), CYP2C9 (i.e., warfarin), CYP2C19 (i.e., omeprazole), CYP1A2 (i.e., caffeine) or CYP2D6 (i.e., dextromethorphan) does not have a clinically significant impact on the pharmacokinetics of these substances.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p><u>Risk Summary</u></p><p>Available data from the published literature and the pharmacovigilance database with TALTZ use in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes.</p><p>&nbsp;Human IgG is known to cross the placental barrier; therefore, TALTZ may be transmitted from the mother to the developing fetus. An embryofetal development study conducted in pregnant monkeys during organogenesis at doses up to 19 times the maximum recommended human dose (MRHD) revealed no evidence of harm to the developing fetus. When dosing was continued until parturition, neonatal deaths were observed at 1.9 times the MRHD <em>[see Data]</em>. The clinical significance of these nonclinical findings is unknown.</p><p>&nbsp;</p><p>The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</p><p><u>Data</u></p><p><em>Animal Data</em></p><p>An embryofetal development study was conducted in cynomolgus monkeys administered ixekizumab. No malformations or embryofetal toxicity were observed in fetuses from pregnant monkeys administered ixekizumab weekly by subcutaneous injection during organogenesis to near parturition at doses up to 19 times the MRHD (on a mg/kg basis of 50&nbsp;mg/kg/week). Ixekizumab crossed the placenta in monkeys.</p><p>In a pre- and post-natal development toxicity study, pregnant cynomolgus monkeys were administered weekly subcutaneous doses of ixekizumab up to 19 times the MRHD from the beginning of organogenesis to parturition. Neonatal deaths occurred in the offspring of two monkeys administered ixekizumab at 1.9 times the MRHD (on a mg/kg basis of 5&nbsp;mg/kg/week) and two monkeys administered ixekizumab at 19 times the MRHD (on a mg/kg basis of 50&nbsp;mg/kg/week). These neonatal deaths were attributed to early delivery, trauma, or congenital defect. The clinical significance of these findings is unknown. No ixekizumab-related effects on functional or immunological development were observed in the surviving infants from birth through 6 months of age.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p><u>Risk Summary</u></p><p>There are no available data on the presence of ixekizumab in human milk, the effects on the breastfed infant, or the effects on milk production. Ixekizumab was detected in the milk of lactating cynomolgus monkeys. When a drug is present in animal milk, it is likely that the drug will be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother&rsquo;s clinical need for TALTZ and any potential adverse effects on the breastfed infant from TALTZ or from the underlying maternal condition.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not available</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">The following adverse drug reactions are discussed in greater detail in other sections of the label:</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp; Infections <em>[see Special warnings and precautions for use (4.4)]</em></p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp; Hypersensitivity Reactions <em>[see Contraindications (4.3) and Special warnings and precautions for use (4.4)]</em></p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Eczematous Eruptions <em>[see </em><em>Special warnings and precautions for use (4.4)]</em></p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp; Inflammatory Bowel Disease <em>[see Special warnings and precautions for use (4.4)]</em></p><p dir="ltr">&nbsp;</p><p dir="ltr">Clinical Trials Experience</p><p dir="ltr">Because clinical trials are conducted under widely varying and controlled conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p><p dir="ltr"><u>Adult Plaque Psoriasis</u></p><p dir="ltr"><em>Weeks 0 to 12</em>:</p><p dir="ltr">Three placebo-controlled trials in subjects with plaque psoriasis were integrated to evaluate the safety of TALTZ compared to placebo for up to 12 weeks. A total of 1167 subjects (mean age 45 years; 66% men; 94% White) with plaque psoriasis received TALTZ (160&nbsp;mg at Week 0, 80&nbsp;mg every 2 weeks [Q2W] for 12 weeks) subcutaneously. In two of the trials, the safety of TALTZ (use up to 12 weeks) was also compared with an active comparator, U.S. approved etanercept <em>[see Pharmacodynamic properties 5.1].</em></p><p dir="ltr">&nbsp;</p><p dir="ltr">In the 12-week, placebo-controlled period, adverse events occurred in 58% of the TALTZ Q2W group (2.5 per subject-year of follow-up) compared with 47% of the placebo group (2.1 per subject-year of follow-up). Serious adverse events occurred in 2% of the TALTZ group (0.07 per subject-year of follow-up), and in 2% of the placebo group (0.07 per subject-year of follow-up).</p><p dir="ltr">Table 1 summarizes the adverse reactions that occurred at a rate of at least 1% and at a higher rate in the TALTZ group than in the placebo group during the 12-week placebo-controlled period of the pooled clinical trials.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Table 1: Adverse Reactions Occurring in &ge;1% of the TALTZ Group and More Frequently than in the Placebo Group in the Plaque Psoriasis Clinical Trials through Week 12</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p><strong>Adverse Reactions</strong></p></td><td style="vertical-align:top"><p><strong>TALTZ 80&nbsp;mg Q2W</strong></p><p><strong>(N=1167) n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Etanercept<sup>b</sup></strong></p><p><strong>(N=287) n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>(N=791) n (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Injection site reactions</strong></p></td><td style="vertical-align:top"><p>196 (17)</p></td><td style="vertical-align:top"><p>32 (11)</p></td><td style="vertical-align:top"><p>26 (3)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Upper respiratory tract infections<sup>a</sup></strong></p></td><td style="vertical-align:top"><p>163 (14)</p></td><td style="vertical-align:top"><p>23 (8)</p></td><td style="vertical-align:top"><p>101 (13)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nausea</strong></p></td><td style="vertical-align:top"><p>23 (2)</p></td><td style="vertical-align:top"><p>1 (&lt;1)</p></td><td style="vertical-align:top"><p>5 (1)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Tinea infections</strong></p></td><td style="vertical-align:top"><p>17 (2)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>1 (&lt;1)</p></td></tr></tbody></table><p dir="ltr"><sup>a</sup>&nbsp;&nbsp;&nbsp; Upper respiratory tract infections cluster includes nasopharyngitis and rhinovirus infection.</p><p dir="ltr"><sup>b</sup>&nbsp;&nbsp;&nbsp; U.S. approved etanercept.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Adverse reactions that occurred at rates less than 1% in the TALTZ group and more frequently than in the placebo group during the 12-week induction period included rhinitis, oral candidiasis, urticaria, influenza, conjunctivitis, inflammatory bowel disease, and angioedema.</p><p dir="ltr"><em>Weeks 13 to 60</em>:</p><p dir="ltr">A total of 332 subjects received the recommended maintenance regimen of TALTZ 80&nbsp;mg dosed every 4&nbsp;weeks.</p><p dir="ltr">During the maintenance period (Weeks 13 to 60), adverse events occurred in 80% of subjects treated with TALTZ (1.0 per subject-year of follow-up) compared to 58% of subjects treated with placebo (1.1 per subject-year of follow-up). Serious adverse events were reported in 4% of subjects treated with TALTZ (0.05 per subject-year of follow-up) and none in the subjects treated with placebo.</p><p dir="ltr"><em>Weeks 0 to 60</em>:</p><p dir="ltr">Over the entire treatment period (Weeks 0 to 60), adverse events were reported in 67% of subjects treated with TALTZ (1.4 per subject-year of follow-up) compared to 48% of subjects treated with placebo (2.0 per subject-year of follow-up). Serious adverse events were reported in 3% of subjects treated with TALTZ (0.06 per subject-year of follow-up), and in 2% of subjects treated with placebo (0.06 per subject-year of follow-up).</p><p dir="ltr"><u>Specific Adverse Drug Reactions</u></p><p dir="ltr"><em>Injection Site Reactions</em></p><p dir="ltr">The most frequent injection site reactions were erythema and pain. Most injection site reactions were mild-to-moderate in severity and did not lead to discontinuation of TALTZ.</p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr"><em>Infections</em></p><p dir="ltr">In the 12-week, placebo-controlled period of the clinical trials in plaque psoriasis, infections occurred in 27% of subjects treated with TALTZ (1.2 per subject-year of follow-up) compared to 23% of subjects treated with placebo (1.0 per subject-year of follow-up). Serious infections occurred in 0.4% of subjects treated with TALTZ (0.02 per subject-year of follow-up) and in 0.4% of subjects treated with placebo (0.02 per subject-year of follow-up) <em>[see Warnings and Precautions (5.1)]</em>.</p><p dir="ltr">&nbsp;</p><p dir="ltr">During the maintenance treatment period (Weeks 13 to 60), infections occurred in 57% of subjects treated with TALTZ (0.70 per subject-year of follow-up) compared to 32% of subjects treated with placebo (0.61 per subject-year of follow-up). Serious infections occurred in 0.9% of subjects treated with TALTZ (0.01 per subject-year of follow-up) and none in the subjects treated with placebo.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Over the entire treatment period (Weeks 0 to 60), infections were reported in 38% of subjects treated with TALTZ (0.83 per subject-year of follow-up) compared to 23% of subjects treated with placebo (1.0 per subject-year of follow-up). Serious infections occurred in 0.7% of subjects treated with TALTZ (0.02 per subject-year of follow-up), and in 0.4% of subject treated with placebo (0.02 per subject-year of follow-up).</p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr"><em>Inflammatory </em><em>Bowel Disease</em></p><p dir="ltr">In<em> </em>adult subjects with plaque psoriasis, Crohn&rsquo;s disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the TALTZ 80&nbsp;mg Q2W group (Crohn&rsquo;s disease 0.1%, ulcerative colitis 0.2%) than the placebo group (0%) during the 12-week, placebo-controlled period in clinical trials <em>[see Spacial Warnings and Precautions for use (4.4)]</em>.</p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr"><em>Laboratory Assessment of Cytopenia</em></p><p dir="ltr">Neutropenia</p><p dir="ltr">Over the entire treatment period (Weeks 0 to 60), neutropenia occurred in 11% of subjects treated with TALTZ (0.24 per subject-year of follow-up) compared to 3% of subjects treated with placebo (0.14 per subject-year of follow-up). In subjects treated with TALTZ, the incidence rate of neutropenia during Weeks 13 to 60 was lower than the incidence rate during Weeks 0 to 12.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In the 12-week, placebo-controlled period, neutropenia &ge; Grade 3 (&lt;1,000 cells/mm<sup>3</sup>) occurred in 0.2% of the TALTZ group (0.007 per subject-year of follow-up) compared to 0.1% of the placebo group (0.006 per subject-year of follow-up). The majority of cases of neutropenia were either Grade 2 (2% for TALTZ 80&nbsp;mg Q2W versus 0.3% for placebo; &ge;1,000 to &lt;1,500 cells/mm<sup>3</sup>) or Grade 1 (7% for TALTZ 80&nbsp;mg Q2W versus 3% for placebo; &ge;1,500 cells/mm<sup>3</sup> to ˂2,000 cells/mm<sup>3</sup>). Neutropenia in the TALTZ group was not associated with an increased rate of infection compared to the placebo group.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Thrombocytopenia</p><p dir="ltr">Ninety eight percent of cases of thrombocytopenia were Grade 1 (3% for TALTZ 80&nbsp;mg Q2W versus 1% for placebo; &ge;75,000 cells/mm<sup>3</sup> to &lt;150,000 cells/mm<sup>3</sup>). Thrombocytopenia in subjects treated with TALTZ was not associated with an increased rate of bleeding compared to subjects treated with placebo.</p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr"><em>Active Comparator Trials</em></p><p dir="ltr">In the two clinical trials that included an active comparator, the rate of serious adverse events during weeks zero to twelve was 0.7% for U.S. approved etanercept and 2% for TALTZ 80&nbsp;mg Q2W, and the rate of discontinuation from adverse events was 0.7% for U.S. approved etanercept and 2% for TALTZ 80&nbsp;mg Q2W. The incidence of infections was 18% for U.S. approved etanercept and 26% for TALTZ 80&nbsp;mg Q2W. The rate of serious infections was 0.3% for both TALTZ 80&nbsp;mg Q2W and U.S. approved etanercept.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Pediatric Plaque Psoriasis</u></p><p dir="ltr">TALTZ was evaluated in a placebo-controlled trial in pediatric subjects with moderate-to-severe psoriasis 6 to less than 18 years of age. A total of 171 subjects were studied (115 subjects on TALTZ and 56 subjects on placebo). Overall, the safety profile observed in pediatric subjects with plaque psoriasis treated with TALTZ every 4 weeks is consistent with the safety profile in adult subjects with plaque psoriasis with the exception of the frequencies of conjunctivitis (2.6%), influenza (1.7%), and urticaria (1.7%).</p><p dir="ltr">In this clinical trial, Crohn&rsquo;s disease occurred at a greater frequency in the TALTZ group (0.9%) than the placebo group (0%) during the 12-week, placebo-controlled period. Crohn&rsquo;s disease occurred in a total of 4 TALTZ treated subjects (2.0%) in the clinical trial <em>[see Warnings and Precautions (5.4)]</em>.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Psoriatic Arthritis</u></p><p dir="ltr">TALTZ was studied in two placebo-controlled trials in patients with psoriatic arthritis. A total of 678 patients were studied (454 patients on TALTZ and 224 on placebo). A total of 229 patients in these trials received TALTZ 160&nbsp;mg at Week 0, followed by 80&nbsp;mg every 4&nbsp;weeks (Q4W). Overall, the safety profile observed in patients with psoriatic arthritis treated with TALTZ Q4W is consistent with the safety profile in adult patients with plaque psoriasis with the exception of the frequencies of influenza (1.3%) and conjunctivitis (1.3%).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Ankylosing Spondylitis</u></p><p dir="ltr">TALTZ was studied in two placebo-controlled trials in patients with ankylosing spondylitis. A total of 566 patients were studied (376 patients on TALTZ and 190 on placebo). A total of 195 patients in these trials received TALTZ 80 or 160&nbsp;mg at Week 0, followed by 80&nbsp;mg every 4&nbsp;weeks (Q4W). Overall, the safety profile observed in patients with ankylosing spondylitis treated with TALTZ Q4W is consistent with the safety profile in adult patients with plaque psoriasis.</p><p dir="ltr">In adult patients with ankylosing spondylitis, Crohn&rsquo;s disease and ulcerative colitis, including exacerbations, occurred in 2 patients (1.0%) and 1 patient (0.5%), respectively, in the TALTZ 80&nbsp;mg Q4W group and 1 patient (0.5%) and 0%, respectively, in the placebo group during the 16-week, placebo-controlled period in clinical trials. Of these patients, serious events occurred in 1 patient in the TALTZ 80&nbsp;mg Q4W group and 1 patient in the placebo group <em>[see Special Warnings and Precautions for Use (4.4)]</em>.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Non--radiographic Axial Spondyloarthritis</u></p><p dir="ltr">TALTZ was studied in a placebo-controlled trial in patients with non-radiographic axial spondyloarthritis. A total of 303 patients were studied (198 patients on TALTZ and 105 on placebo). A total of 96 patients in this trial received TALTZ 80 or 160&nbsp;mg at Week 0, followed by 80&nbsp;mg every 4&nbsp;weeks (Q4W). Overall, the safety profile observed in patients with non-radiographic axial spondyloarthritis treated with TALTZ 80&nbsp;mg Q4W up to Week 16 is consistent with the previous experience of TALTZ in other indications.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Immunogenicity</p><p dir="ltr">As with all therapeutic proteins there is the potential for immunogenicity with TALTZ. The assay to test for neutralizing antibodies has limitations detecting neutralizing antibodies in the presence of ixekizumab; therefore, the incidence of neutralizing antibodies development could be underestimated.</p><p dir="ltr"><u>Plaque Psoriasis Population</u></p><p dir="ltr">By Week 12, approximately 9% of adult subjects treated with TALTZ every 2 weeks developed antibodies to ixekizumab. Approximately 22% of subjects treated with TALTZ at the recommended dosing regimen developed antibodies to ixekizumab during the 60-week treatment period. The clinical effects of antibodies to ixekizumab are dependent on the antibody titer; higher antibody titers were associated with decreasing drug concentration and clinical response.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Of the adult subjects who developed antibodies to ixekizumab during the 60-week treatment period, approximately 10%, which equates to 2% of subjects treated with TALTZ at the recommended dosing regimen, had antibodies that were classified as neutralizing. Neutralizing antibodies were associated with reduced drug concentrations and loss of efficacy.</p><p dir="ltr">In pediatric psoriasis subjects treated with ixekizumab at the recommended dosing regimen up to 12 weeks, 21&nbsp;subjects (18%) developed anti-drug antibodies, 5 subjects (4%) had confirmed neutralizing antibodies associated with low drug concentrations. No conclusive evidence could be obtained on the potential association of neutralizing antibodies and clinical response and/or adverse events due to small number of pediatric subjects in the study.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Psoriatic Arthritis Population</u></p><p dir="ltr">For subjects treated with TALTZ 80&nbsp;mg every 4&nbsp;weeks for up to 52 weeks (PsA1), 11% developed anti-drug antibodies, and 8% had confirmed neutralizing antibodies.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Ankylosing Spondylitis Population</u></p><p dir="ltr">For patients treated with TALTZ 80&nbsp;mg every 4&nbsp;weeks for up to 16 weeks (AS1, AS2), 5.2% developed anti-drug antibodies, and 1.5% had neutralizing antibodies.</p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><u>Non-radiographic Axial Spondyloarthritis Population</u></p><p dir="ltr">Of patients treated with TALTZ 80&nbsp;mg every 4&nbsp;weeks for up to 52 weeks (nr-axSpA1), 8.9% developed anti-drug antibodies, all of which were low titer. No patient had neutralizing antibodies.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of incidence of antibodies to TALTZ across indications or with the incidences of antibodies to other products may be misleading.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Postmarketing Experience</p><p dir="ltr">The following adverse reactions have been identified during post-approval use of TALTZ. Because the reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to TALTZ exposure.</p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr"><em>Immune system disorders:</em> anaphylaxis <em>[see Contraindications (4.3) </em></p><p dir="ltr">&nbsp;</p><p><em>Infections:</em> bacterial, viral, and fungal opportunistic infections, including cryptococcal meningoencephalitis, esophageal and disseminated mucocutaneous candidiasis, pulmonary tuberculosis, toxoplasmosis, varicella zoster virus reactivation, cytomegalovirus colitis, pulmonary aspergillosis.</p><p><em>Skin and subcutaneous tissue disorders</em>: Eczematous eruptions (erythroderma, atopic dermatitis-like eruptions, and dyshidrotic eczema)<em>.</em></p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p dir="ltr">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed below.</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p><strong>&nbsp;</strong></p><p>The National Pharmacovigilance Center (NPC):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">No object.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pharmacotherapeutic group: Immunosuppressants, interleukin inhibitors, ATC code: L04AC13</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Mechanism of action</u></p><p dir="ltr">Ixekizumab is a humanized IgG4 monoclonal antibody that selectively binds with the interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Ixekizumab inhibits the release of proinflammatory cytokines and chemokines.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Pharmacodynamic effects</u></p><p dir="ltr">No formal pharmacodynamic studies have been conducted with TALTZ.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Clinical studies</u></p><p dir="ltr">Adult Plaque Psoriasis</p><p dir="ltr">Three multicenter, randomized, double-blind, placebo-controlled trials, Trials 1, 2, and 3 (NCT&nbsp;01474512, NCT&nbsp;01597245, NCT&nbsp;01646177), enrolled a total of 3866 subjects 18 years of age and older with plaque psoriasis who had a minimum body surface area involvement of 10%, a static Physician Global Assessment (sPGA) score of &ge;3 in the overall assessment (plaque thickness/induration, erythema, and scaling) of psoriasis on a severity scale of 0 to 5, a Psoriasis Area and Severity Index (PASI) score &ge;12, and who were candidates for phototherapy or systemic therapy.</p><p dir="ltr">In all three trials, subjects were randomized to either placebo or TALTZ (80&nbsp;mg every 2 weeks [Q2W]) for 12&nbsp;weeks, following a 160&nbsp;mg starting dose. In the two active comparator trials (Trials 2 and 3), subjects were also randomized to receive U.S. approved etanercept 50&nbsp;mg twice weekly for 12&nbsp;weeks.</p><p dir="ltr">&nbsp;</p><p dir="ltr">All three trials assessed the changes from baseline to Week 12 in the two co-primary endpoints: 1) PASI 75, the proportion of subjects who achieved at least a 75% reduction in the PASI composite score that takes into consideration both the percentage of body surface area affected and the nature and severity of psoriatic changes (induration, erythema and scaling) within the affected regions, and 2) sPGA of &ldquo;0&rdquo; (clear) or &ldquo;1&rdquo; (minimal), the proportion of subjects with an sPGA 0 or 1 and at least a 2-point improvement.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Other evaluated outcomes included the proportion of subjects with an sPGA score of 0 (clear), a reduction of at least 90% in PASI (PASI 90), a reduction of 100% in PASI (PASI 100), and an improvement of itch severity as measured by a reduction of at least 4 points on an 11-point itch Numeric Rating Scale.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Subjects in all treatment groups had a median baseline PASI score ranging from approximately 17 to 18. Baseline sPGA score was severe or very severe in 51% of subjects in Trial 1, 50% in Trial 2, and 48% in Trial 3.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Of all subjects, 44% had received prior phototherapy, 49% had received prior conventional systemic therapy, and 26% had received prior biologic therapy for the treatment of psoriasis. Of the subjects who had received prior biologic therapy, 15% had received at least one anti-TNF alpha agent, and 9% had received an anti-IL 12/IL23. A total of 23% of study subjects had a history of psoriatic arthritis.</p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><u>Clinical Response at Week 12</u></p><p dir="ltr">The results of Trials 1, 2, and 3 are presented in Table 2.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Table 2: Efficacy Results at Week 12 in Adults with Plaque Psoriasis in Trials 1, 2, and 3; NRI<sup>a</sup></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:690px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Trial 1</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Trial 2</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Trial 3</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>TALTZ 80&nbsp;mg<sup>b</sup></strong></p><p><strong>Q2W (N=433)</strong></p><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>(N=431)</strong></p><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>TALTZ 80&nbsp;mg<sup>b</sup></strong></p><p><strong>Q2W (N=351)</strong></p><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>(N=168)</strong></p><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>TALTZ 80&nbsp;mg<sup>b</sup></strong></p><p><strong>Q2W (N=385)</strong></p><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>(N=193)</strong></p><p><strong>n (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>sPGA of &ldquo;0&rdquo; (clear) or &ldquo;1&rdquo; (minimal)<sup>c</sup></strong></p></td><td style="vertical-align:top"><p>354 (82)</p></td><td style="vertical-align:top"><p>14 (3)</p></td><td style="vertical-align:top"><p>292 (83)</p></td><td style="vertical-align:top"><p>4 (2)</p></td><td style="vertical-align:top"><p>310 (81)</p></td><td style="vertical-align:top"><p>13 (7)</p></td></tr><tr><td><p><strong>sPGA of &ldquo;0&rdquo; (clear)</strong></p></td><td style="vertical-align:top"><p>160 (37)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>147 (42)</p></td><td style="vertical-align:top"><p>1 (1)</p></td><td style="vertical-align:top"><p>155 (40)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p><strong>PASI 75<sup>c</sup></strong></p></td><td style="vertical-align:top"><p>386 (89)</p></td><td style="vertical-align:top"><p>17 (4)</p></td><td style="vertical-align:top"><p>315 (90)</p></td><td style="vertical-align:top"><p>4 (2)</p></td><td><p>336 (87)</p></td><td style="vertical-align:top"><p>14 (7)</p></td></tr><tr><td style="vertical-align:top"><p><strong>PASI 90</strong></p></td><td style="vertical-align:top"><p>307 (71)</p></td><td style="vertical-align:top"><p>2 (1)</p></td><td style="vertical-align:top"><p>248 (71)</p></td><td><p>1 (1)</p></td><td style="vertical-align:top"><p>262 (68)</p></td><td style="vertical-align:top"><p>6 (3)</p></td></tr><tr><td style="vertical-align:top"><p><strong>PASI 100</strong></p></td><td style="vertical-align:top"><p>153 (35)</p></td><td style="vertical-align:top"><p>0</p></td><td><p>142 (40)</p></td><td style="vertical-align:top"><p>1 (1)</p></td><td style="vertical-align:top"><p>145 (38)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Itch NRS (&ge;4 point improvement)<sup>d</sup></strong></p></td><td style="vertical-align:top"><p>336 (86)</p></td><td style="vertical-align:top"><p>58 (16)</p></td><td><p>258 (85)</p></td><td style="vertical-align:top"><p>19 (14)</p></td><td style="vertical-align:top"><p>264 (83)</p></td><td style="vertical-align:top"><p>33 (21)</p></td></tr></tbody></table><p dir="ltr"><sup>a</sup>&nbsp;&nbsp;&nbsp; Abbreviations: N = number of patients in the intent-to-treat population; NRI = Non-Responder Imputation.</p><p dir="ltr"><sup>b</sup>&nbsp;&nbsp;&nbsp; At Week 0, subjects received 160&nbsp;mg of TALTZ.</p><p dir="ltr"><sup>c&nbsp; &nbsp;&nbsp;&nbsp;</sup>Co-primary endpoint</p><p dir="ltr"><sup>d &nbsp;&nbsp;&nbsp;&nbsp;</sup>Itch NRS (&ge;4 improvement) in subjects with baseline Itch NRS &ge;4. The number of ITT subjects with baseline Itch NRS Score &ge;4 are as follows: Trial 1, TALTZ n=391, PBO n=374; Trial 2, TALTZ n=303, PBO n=135; Trial 3, TALTZ n=320, PBO n=158.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Examination of age, gender, race, body weight, and previous treatment with a biologic did not identify differences in response to TALTZ among these subgroups at Week 12.</p><p dir="ltr">&nbsp;</p><p dir="ltr">An integrated analysis of the U.S. sites in the two active comparator studies using U.S. approved etanercept, TALTZ demonstrated superiority to U.S. approved etanercept (50&nbsp;mg twice weekly) on sPGA and PASI scores during the 12 week treatment period. The respective response rates for TALTZ 80&nbsp;mg Q2W and U.S. approved etanercept 50&nbsp;mg twice weekly were: sPGA of 0 or 1 (73% and 27%); PASI 75 (87% and 41%); sPGA of 0 (34% and 5%); PASI 90 (64% and 18%), and PASI 100 (34% and 4%).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Maintenance and Durability of Response</u></p><p dir="ltr">To evaluate the maintenance and durability of response, subjects originally randomized to TALTZ and who were responders at Week 12 (i.e., sPGA of 0 or 1) in Trial 1 and Trial 2 were re-randomized to an additional 48 weeks of either a maintenance dose of TALTZ 80&nbsp;mg Q4W (every 4 weeks) or placebo. Non-responders (sPGA &gt;1) at Week 12 and subjects who relapsed (sPGA &ge;3) during the maintenance period were placed on TALTZ 80&nbsp;mg Q4W.</p><p dir="ltr">&nbsp;</p><p dir="ltr">For responders at Week 12, the percentage of subjects who maintained this response (sPGA 0 or 1) at Week 60 (48 weeks following re-randomization) in the integrated trials (Trial 1 and Trial 2) was higher for subjects treated with TALTZ 80&nbsp;mg Q4W (75%) compared to those treated with placebo (7%).</p><p dir="ltr">&nbsp;</p><p dir="ltr">For responders at Week 12 who were re-randomized to treatment withdrawal (i.e., placebo), the median time to relapse (sPGA &ge;3) was 164 days in the integrated trials. Among these subjects, 66% regained a response of at least 0 or 1 on the sPGA within 12 weeks of restarting treatment with TALTZ 80&nbsp;mg Q4W.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Psoriasis Involving the Genital Area</u></p><p dir="ltr">A randomized, double-blind, placebo-controlled trial (Trial 4) was conducted in 149 adult subjects with plaque psoriasis who had a minimum body surface area (BSA) involvement of 1%, a sPGA score of &ge;3 (moderate psoriasis), a sPGA of Genitalia score of &ge;3 (moderate psoriasis involving the genital area), who failed to respond to or were intolerant of at least one topical therapy used for treatment of psoriasis affecting the genital area, and who were candidates for phototherapy and/or systemic therapy.</p><p dir="ltr">Subjects had a median baseline PASI score of approximately 12. Baseline BSA involvement was at least 10% for approximately 60% of the enrolled subjects. Baseline sPGA of Genitalia score was severe or very severe in approximately 42% of the subjects; baseline sPGA score was severe or very severe in approximately 47% of the subjects.</p><p dir="ltr">Subjects randomized to TALTZ received an initial dose of 160&nbsp;mg followed by 80&nbsp;mg every 2 weeks for 12 weeks. The trial evaluated the primary endpoint of the proportion of subjects who achieved a &ldquo;0&rdquo; (clear) or &ldquo;1&rdquo; (minimal) response at Week 12 on sPGA of Genitalia. Other evaluated outcomes at Week 12 included the proportion of subjects who achieved a sPGA score of &ldquo;0&rdquo; (clear) or &ldquo;1&rdquo; (minimal), improvement of genital itch severity as measured by a reduction of at least 4 points in the 11-point Genital Psoriasis Symptoms Scale (GPSS) score Itch numeric rating scale (NRS), and the patient-perceived impact of psoriasis affecting the genital area on limiting frequency of sexual activity (intercourse or other activities) as measured by the Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) Item 2 (In the past week how often did your genital psoriasis limit the frequency of your sexual activity?). SFQ Item 2 score ranges from 0 to 4 (0=never, 1=rarely, 2=sometimes, 3=often, 4=always); where higher scores indicate greater limitations on the frequency of sexual activity in the past week.</p><p dir="ltr">The results of Trial 4 are presented in Table 3.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Table 3: Efficacy Results at Week 12 in Adults with Genital Psoriasis in Trial 4; NRI<sup>a</sup></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:726px"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoints</strong></p></td><td style="vertical-align:top"><p><strong>TALTZ 80&nbsp;mg Q2W<sup>b</sup></strong></p><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>n (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Number of subjects randomized</strong></p></td><td style="vertical-align:top"><p><strong>N=75</strong></p></td><td style="vertical-align:top"><p><strong>N=74</strong></p></td></tr><tr><td style="vertical-align:top"><p>sPGA of Genitalia &ldquo;0&rdquo; (clear) or &ldquo;1&rdquo; (minimal)</p></td><td style="vertical-align:top"><p>55 (73%)</p></td><td style="vertical-align:top"><p>6 (8%)</p></td></tr><tr><td style="vertical-align:top"><p>sPGA &ldquo;0&rdquo; (clear) or &ldquo;1&rdquo; (minimal)</p></td><td style="vertical-align:top"><p>55 (73%)</p></td><td style="vertical-align:top"><p>2 (3%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Number of subjects with baseline GPSS<sup>a</sup> Itch NRS Score &ge;4</strong></p></td><td style="vertical-align:top"><p><strong>N=56</strong></p></td><td style="vertical-align:top"><p><strong>N=51</strong></p></td></tr><tr><td style="vertical-align:top"><p>GPSS Genital Itch (&ge;4 point improvement)</p></td><td style="vertical-align:top"><p>31 (55%)</p></td><td style="vertical-align:top"><p>3 (6%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Number of subjects with baseline GenPs-SFQ<sup>a</sup> Item 2 Score &ge;2</strong></p></td><td style="vertical-align:top"><p><strong>N=37</strong></p></td><td style="vertical-align:top"><p><strong>N=42</strong></p></td></tr><tr><td style="vertical-align:top"><p>GenPs-SFQ Item 2 score &ldquo;0&rdquo; (never) or &ldquo;1&rdquo; (rarely)</p></td><td style="vertical-align:top"><p>29 (78%)</p></td><td style="vertical-align:top"><p>9 (21%)</p></td></tr></tbody></table><p dir="ltr"><sup>a</sup>&nbsp;&nbsp;&nbsp; Abbreviations: NRI = Non-Responder Imputation; GPSS = Genital Psoriasis Symptoms Scale; GenPs-SFQ = Genital Psoriasis Sexual Frequency Questionnaire.</p><p dir="ltr"><sup>b</sup>&nbsp;&nbsp;&nbsp; At Week 0, subjects received 160&nbsp;mg of TALTZ, followed by 80&nbsp;mg every 2 weeks for 12 weeks.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Pediatric Plaque Psoriasis</p><p dir="ltr">A randomized, double-blind, multicenter, placebo-controlled trial (IXORA-Peds, NCT03073200) enrolled 171 pediatric subjects 6 to less than 18 years of age, with moderate-to-severe plaque psoriasis (as defined by a sPGA score &ge;3, involving &ge;10% of the body surface area, and a PASI score &ge;12) who were candidates for phototherapy or systemic therapy or were inadequately controlled on topical therapy.</p><p dir="ltr">Subjects were randomized to placebo or TALTZ with dosing stratified by weight. A total of 147 subjects had a body weight of more than 50 kg. Subjects above 50 kg in the ixekizumab arm (n=84) received 160 mg at week 0 followed by 80 mg Q4W.</p><p dir="ltr">Response to treatment was assessed at 12 weeks of therapy and was defined by the proportion of subjects who achieved an sPGA score of &ldquo;0&rdquo; (clear) or &ldquo;1&rdquo; (almost clear) with at least a 2 point improvement from baseline and the proportion of subjects that achieved a reduction in PASI score of at least 75% (PASI 75) from baseline.</p><p dir="ltr">Other evaluated outcomes included the proportion of subjects who achieved PASI 90, PASI 100, sPGA of &ldquo;0&rdquo; and an improvement of itch severity as measured by a reduction of at least 4 points on an 11-point itch Numeric Rating Scale.</p><p dir="ltr">Looking at the entire study population, subjects had a median baseline PASI score of 17 (range 12-49). Baseline sPGA score was severe or very severe in 49%. Of all subjects, 22% had received prior phototherapy and 32% had received prior conventional systemic therapy for the treatment of psoriasis.</p><p dir="ltr"><u>Clinical Response</u></p><p dir="ltr">The efficacy results of IXORA-Peds are presented in Table 4.</p><p dir="ltr"><s>&nbsp;</s></p><p dir="ltr">Table 4: Efficacy Results in Pediatric Subjects with Plaque Psoriasis in IXORA-Peds, NRI<sup>a</sup></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>TALTZ<sup>b</sup><br />(N=115)<br />n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo<br />(N=56)<br />n (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Week 12</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>sPGA &ldquo;0&rdquo; (clear) or &ldquo;1&rdquo; (minimal)<sup>c</sup></strong></p></td><td style="vertical-align:top"><p>93 (81%)</p></td><td style="vertical-align:top"><p>6 (11%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>sPGA &ldquo;0&rdquo; (clear)</strong></p></td><td style="vertical-align:top"><p>60 (52%)</p></td><td style="vertical-align:top"><p>1 (2%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>PASI 75<sup>c</sup></strong></p></td><td style="vertical-align:top"><p>102 (89%)</p></td><td style="vertical-align:top"><p>14 (25%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>PASI 90</strong></p></td><td style="vertical-align:top"><p>90 (78%)</p></td><td style="vertical-align:top"><p>3 (5%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>PASI 100</strong></p></td><td style="vertical-align:top"><p>57 (50%)</p></td><td style="vertical-align:top"><p>1 (2%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Itch NRS (&ge;4 point improvement)<sup>d</sup></strong></p></td><td style="vertical-align:top"><p>59 (71%)</p></td><td style="vertical-align:top"><p>8 (20%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Week 4</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>sPGA &ldquo;0&rdquo; (clear) or &ldquo;1&rdquo; (minimal)</strong></p></td><td style="vertical-align:top"><p>55 (48%)</p></td><td style="vertical-align:top"><p>4 (7%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>PASI 75</strong></p></td><td style="vertical-align:top"><p>62 (54%)</p></td><td style="vertical-align:top"><p>5 (9%)</p></td></tr></tbody></table><p dir="ltr"><sup>a</sup>&nbsp;&nbsp;&nbsp; Abbreviations: N = Number of subjects in the intent-to-treat population; NRI = Non-Responder Imputation.</p><p dir="ltr"><sup>b</sup>&nbsp;&nbsp;&nbsp; All subjects receiving TALTZ, for 12 weeks, independent of weight category.</p><p dir="ltr"><sup>c</sup>&nbsp;&nbsp;&nbsp; Co-primary endpoints.</p><p dir="ltr"><sup>d</sup>&nbsp;&nbsp;&nbsp; Itch NRS (&ge;4 improvement) in subjects with baseline Itch NRS &ge;4. The number of ITT subjects with baseline Itch NRS Score &ge;4 are as follows: TALTZ, n = 83; PBO, n = 40.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Psoriatic Arthritis</p><p dir="ltr">The safety and efficacy of TALTZ were assessed in 679 patients, in 2 randomized, double-blind, placebo-controlled studies (PsA1 and PsA2) in adult patients, age 18 years and older with active psoriatic arthritis (at least 3 swollen and at least 3 tender joints) despite non-steroidal anti-inflammatory drug (NSAID), corticosteroid or disease modifying anti-rheumatic drug (DMARD) therapy. Patients in these studies had a diagnosis of PsA for at least 6 months across both studies. At baseline, 60% and 23% of the patients had enthesitis and dactylitis, respectively. In PsA2, all patients discontinued previous treatment with anti-TNF&alpha; agents due to either inadequate response or intolerance. In addition, approximately 47% of patients from both studies had concomitant methotrexate (MTX) use.</p><p dir="ltr">&nbsp;</p><p dir="ltr">PsA1 Study (NCT&nbsp;01695239) evaluated 417 biologic-naive patients, who were treated with either TALTZ 160&nbsp;mg at Week&nbsp;0 followed by 80&nbsp;mg every 2&nbsp;weeks (Q2W) or 4&nbsp;weeks (Q4W), adalimumab 40&nbsp;mg every 2&nbsp;weeks, or placebo. PsA2 Study (NCT&nbsp;02349295) evaluated 363 anti-TNF&alpha; experienced patients, who were treated with TALTZ 160 mg at Week 0 followed by 80&nbsp;mg every 2 or 4&nbsp;weeks, or placebo. Patients receiving placebo were re-randomized to receive TALTZ (80&nbsp;mg every 2 or 4&nbsp;weeks) at Week&nbsp;16 or Week&nbsp;24 based on responder status. The primary endpoint was the percentage of patients achieving an ACR20 response at Week&nbsp;24.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Clinical Response</u></p><p dir="ltr">In both studies, patients treated with TALTZ 80&nbsp;mg Q4W demonstrated a greater clinical response including ACR20, ACR50, and ACR70 compared to placebo at Week 24 (Table 5). In PsA2, responses were seen regardless of prior anti-TNF&alpha; exposure.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Table 5: Responses<sup>a</sup> at Week 12 and 24; NRI<sup>b</sup></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>PsA1 &ndash; anti-TNF&alpha; naive</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>PsA2 &ndash; anti-TNF&alpha; &ndash; experienced</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>TALTZ</strong></p><p><strong>80&nbsp;mg<sup>c</sup></strong></p><p><strong>Q4W</strong></p><p><strong>(N=107)</strong></p></td><td><p><strong>Placebo (N=106)</strong></p></td><td><p><strong>Difference from placebo (95% CI)</strong></p></td><td style="vertical-align:top"><p><strong>TALTZ</strong></p><p><strong>80&nbsp;mg<sup>c</sup></strong></p><p><strong>Q4W</strong></p><p><strong>(N=122)</strong></p></td><td><p><strong>Placebo (N=118)</strong></p></td><td><p><strong>Difference from placebo (95% CI)</strong></p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>ACR20 response</strong></p></td></tr><tr><td style="vertical-align:top"><p>Week 12 (%)</p></td><td style="vertical-align:top"><p>57</p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>26 (13, 39)</p></td><td style="vertical-align:top"><p>50</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>28 (16, 40)</p></td></tr><tr><td style="vertical-align:top"><p>Week 24 (%)</p></td><td style="vertical-align:top"><p>58</p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>28 (15, 41)</p></td><td style="vertical-align:top"><p>53</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>34 (22, 45)</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>ACR50 response</strong></p></td></tr><tr><td style="vertical-align:top"><p>Week 12 (%)</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>29 (19, 39)</p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>28 (19, 37)</p></td></tr><tr><td style="vertical-align:top"><p>Week 24 (%)</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>25 (14, 37)</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>30 (21, 40)</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>ACR70 response</strong></p></td></tr><tr><td style="vertical-align:top"><p>Week 12 (%)</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>15 (8, 22)</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>13 (6, 20)</p></td></tr><tr><td style="vertical-align:top"><p>Week 24 (%)</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>18 (9, 27)</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>22 (15, 30)</p></td></tr></tbody></table><p dir="ltr"><sup>a</sup>&nbsp;&nbsp;&nbsp; Patients who met escape criteria (less than 20% improvement in tender and swollen joint counts) at Week 16 or had missing data at Week 24 were considered non-responders at Week 24.</p><p dir="ltr"><sup>b</sup>&nbsp;&nbsp;&nbsp; Abbreviations: N = number of patients in the intent-to-treat population; NRI = Non-Responder Imputation.</p><p dir="ltr"><sup>c</sup>&nbsp;&nbsp;&nbsp; At Week 0, patients received 160&nbsp;mg of TALTZ.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The percentage of patients achieving ACR20 response by visit is shown in Figure 1.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Figure 1: Percent of Patients Achieving ACR20 Response<sup>a</sup> in PsA1 Through Week 24</p><p dir="ltr"><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_3" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:397.5pt;height:252pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/L011405/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
  o:title="High Res_Negotiation_USPI ACR20 - RHAP"/>
</v:shape><![endif]--><img width="530" height="336" alt="" src="file:///C:/Users/L011405/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></p><p dir="ltr"><sup>a</sup>&nbsp;&nbsp;&nbsp; Patients who met escape criteria (less than 20% improvement in tender and swollen joint counts) at Week&nbsp;16 or had missing data at Week 24 were considered non-responders at Week&nbsp;24.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The improvements in the components of the ACR response criteria are shown in Table&nbsp;6.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Table 6: Efficacy results in ACR Components at Week 12 and 16</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:684px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>PsA1</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>PsA2</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>TALTZ 80&nbsp;mg<sup>a</sup></strong></p><p><strong>Q4W (N=107)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>(N=106)</strong></p></td><td style="vertical-align:top"><p><strong>TALTZ 80&nbsp;mg<sup>a</sup></strong></p><p><strong>Q4W (N=122)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>(N=118)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>No. of Swollen Joints</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Baseline</p></td><td style="vertical-align:top"><p>11.4</p></td><td style="vertical-align:top"><p>10.6</p></td><td style="vertical-align:top"><p>13.1</p></td><td style="vertical-align:top"><p>10.3</p></td></tr><tr><td style="vertical-align:top"><p>Mean Change at Week 12</p></td><td style="vertical-align:top"><p>-6.2</p></td><td style="vertical-align:top"><p>-3.2</p></td><td style="vertical-align:top"><p>-5.8</p></td><td style="vertical-align:top"><p>-2.6</p></td></tr><tr><td style="vertical-align:top"><p>Mean Change at Week 16</p></td><td style="vertical-align:top"><p>-6.2</p></td><td style="vertical-align:top"><p>-3.0</p></td><td style="vertical-align:top"><p>-7.4</p></td><td style="vertical-align:top"><p>-2.6</p></td></tr><tr><td style="vertical-align:top"><p><strong>No. of Tender Joints</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Baseline</p></td><td style="vertical-align:top"><p>20.5</p></td><td style="vertical-align:top"><p>19.2</p></td><td style="vertical-align:top"><p>22.0</p></td><td style="vertical-align:top"><p>23.0</p></td></tr><tr><td style="vertical-align:top"><p>Mean Change at Week 12</p></td><td style="vertical-align:top"><p>-10.3</p></td><td style="vertical-align:top"><p>-3.5</p></td><td style="vertical-align:top"><p>-9.4</p></td><td style="vertical-align:top"><p>-5.4</p></td></tr><tr><td style="vertical-align:top"><p>Mean Change at Week 16</p></td><td style="vertical-align:top"><p>-9.7</p></td><td style="vertical-align:top"><p>-4.0</p></td><td style="vertical-align:top"><p>-10.1</p></td><td style="vertical-align:top"><p>-3.0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Patient&rsquo;s Assessment of Pain</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Baseline</p></td><td style="vertical-align:top"><p>60.1</p></td><td style="vertical-align:top"><p>58.5</p></td><td style="vertical-align:top"><p>63.9</p></td><td style="vertical-align:top"><p>63.9</p></td></tr><tr><td style="vertical-align:top"><p>Mean Change at Week 12</p></td><td style="vertical-align:top"><p>-26.6</p></td><td style="vertical-align:top"><p>-9.1</p></td><td style="vertical-align:top"><p>-29.8</p></td><td style="vertical-align:top"><p>-11.9</p></td></tr><tr><td style="vertical-align:top"><p>Mean Change at Week 16</p></td><td style="vertical-align:top"><p>-26.1</p></td><td style="vertical-align:top"><p>-10.6</p></td><td style="vertical-align:top"><p>-30.1</p></td><td style="vertical-align:top"><p>-12.3</p></td></tr><tr><td style="vertical-align:top"><p><strong>Patient Global Assessment</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Baseline</p></td><td style="vertical-align:top"><p>62.7</p></td><td style="vertical-align:top"><p>61.1</p></td><td style="vertical-align:top"><p>66.4</p></td><td style="vertical-align:top"><p>64.1</p></td></tr><tr><td style="vertical-align:top"><p>Mean Change at Week 12</p></td><td style="vertical-align:top"><p>-29.7</p></td><td style="vertical-align:top"><p>-11.1</p></td><td style="vertical-align:top"><p>-34.5</p></td><td style="vertical-align:top"><p>-10.7</p></td></tr><tr><td style="vertical-align:top"><p>Mean Change at Week 16</p></td><td style="vertical-align:top"><p>-30.4</p></td><td style="vertical-align:top"><p>-13.2</p></td><td style="vertical-align:top"><p>-35.3</p></td><td style="vertical-align:top"><p>-15.7</p></td></tr><tr><td style="vertical-align:top"><p><strong>Physician Global Assessment</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Baseline</p></td><td style="vertical-align:top"><p>57.6</p></td><td style="vertical-align:top"><p>55.9</p></td><td style="vertical-align:top"><p>60.3</p></td><td style="vertical-align:top"><p>58.9</p></td></tr><tr><td style="vertical-align:top"><p>Mean Change at Week 12</p></td><td style="vertical-align:top"><p>-34.0</p></td><td style="vertical-align:top"><p>-16.6</p></td><td style="vertical-align:top"><p>-34.4</p></td><td style="vertical-align:top"><p>-15.9</p></td></tr><tr><td style="vertical-align:top"><p>Mean Change at Week 16</p></td><td style="vertical-align:top"><p>-35.5</p></td><td style="vertical-align:top"><p>-16.5</p></td><td style="vertical-align:top"><p>-32.9</p></td><td style="vertical-align:top"><p>-9.7</p></td></tr><tr><td style="vertical-align:top"><p><strong>Disability Index (HAQ-DI)<sup>b</sup></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Baseline</p></td><td style="vertical-align:top"><p>1.2</p></td><td style="vertical-align:top"><p>1.2</p></td><td style="vertical-align:top"><p>1.2</p></td><td style="vertical-align:top"><p>1.2</p></td></tr><tr><td style="vertical-align:top"><p>Mean Change at Week 12</p></td><td style="vertical-align:top"><p>-0.4</p></td><td style="vertical-align:top"><p>-0.1</p></td><td style="vertical-align:top"><p>-0.4</p></td><td style="vertical-align:top"><p>-0.1</p></td></tr><tr><td style="vertical-align:top"><p>Mean Change at Week 16</p></td><td style="vertical-align:top"><p>-0.4</p></td><td style="vertical-align:top"><p>-0.1</p></td><td style="vertical-align:top"><p>-0.5</p></td><td style="vertical-align:top"><p>-0.1</p></td></tr><tr><td style="vertical-align:top"><p><strong>CRP (mg/L)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Baseline</p></td><td style="vertical-align:top"><p>12.8</p></td><td style="vertical-align:top"><p>15.1</p></td><td style="vertical-align:top"><p>17.0</p></td><td style="vertical-align:top"><p>12.1</p></td></tr><tr><td style="vertical-align:top"><p>Mean Change at Week 12</p></td><td style="vertical-align:top"><p>-8.8</p></td><td style="vertical-align:top"><p>-3.2</p></td><td style="vertical-align:top"><p>-11.4</p></td><td style="vertical-align:top"><p>-4.3</p></td></tr><tr><td style="vertical-align:top"><p>Mean Change at Week 16</p></td><td style="vertical-align:top"><p>-9.3</p></td><td style="vertical-align:top"><p>-3.2</p></td><td style="vertical-align:top"><p>-11.2</p></td><td style="vertical-align:top"><p>-5.9</p></td></tr></tbody></table><p dir="ltr"><sup>a</sup>&nbsp;&nbsp;&nbsp; At Week 0, subjects received 160&nbsp;mg of TALTZ.</p><p dir="ltr"><sup>b</sup>&nbsp;&nbsp;&nbsp; Disability Index of the Health Assessment Questionnaire; 0 = best, 3 = worst, measures the patient&rsquo;s ability to perform the following: dress/groom, arise, eat, walk, reach, grip, maintain hygiene, and maintain daily activity.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Treatment with TALTZ resulted in improvement in dactylitis and enthesitis in patients with pre-existing dactylitis or enthesitis.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Treatment with TALTZ 80&nbsp;mg Q4W resulted in an improvement in psoriatic skin lesions in patients with PsA.</p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr"><em>Radiographic Response</em></p><p dir="ltr">Radiographic changes were assessed in PsA1. Inhibition of progression of structural damage was assessed radiographically and expressed as the change in modified total Sharp score (mTSS) at Week&nbsp;16, compared to baseline. The total Sharp score was modified for psoriatic arthritis by addition of hand distal interphalangeal (DIP) joints.</p><p dir="ltr">&nbsp;</p><p dir="ltr">TALTZ 80&nbsp;mg Q4W inhibited the progression of structural joint damage (mTSS) compared to placebo at Week&nbsp;16. The adjusted mean change from baseline in the mTSS was 0.13 for TALTZ 80&nbsp;mg Q4W and 0.36 for placebo (difference in means TALTZ minus placebo: &shy;0.23, 95% CI: (&shy;0.42, &shy;0.04)).</p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr"><em>Physical Function</em></p><p dir="ltr">TALTZ treated patients showed improvement in physical function compared to patients treated with placebo as assessed by the Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 12 and 24. In both studies, the proportion of HAQ-DI responders (&ge;0.35 improvement in HAQ-DI score) was greater in the TALTZ 80&nbsp;mg Q4W groups compared to placebo at week 12 and 24.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Postmarketing Phase 4, direct comparative study</em></p><p dir="ltr">Efficacy and safety of Taltz was investigated in a multicenter, randomized, open-label, rater-blinded, parallel-group study (SPIRIT-H2H) compared to adalimumab (ADA)<em> </em>in 566&nbsp;patients with PsA who were na&iuml;ve to biologic disease-modifying anti-rheumatic drugs (bDMARD). Patients were stratified at baseline based on concomitant cDMARD use and presence of moderate-to-severe psoriasis (PASI&ge;12, BSA&ge;10 and sPGA&ge;3).</p><p dir="ltr">Taltz was superior to ADA on the primary study objective: simultaneous achievement of ACR&nbsp;50 and PASI&nbsp;100 response at Week&nbsp;24 (Taltz 36.0% vs ADA 27.9%; p=0.036; 95% confidence interval [0.5%, 15.8%]). Taltz also showed non-inferiority (pre-specified margin of -12%) to ADA on ACR&nbsp;50 (ITT analysis: Taltz 50.5% vs ADA 46.6%; 3.9% difference vs. ADA; 95% confidence interval [-4.3%; 12.1%]&nbsp;; PPS analysis Taltz: 52.3%, ADA: 53.1%, difference: -0.8% [CI: -10.3%; 8.7%])<em> </em>and superiority on PASI&nbsp;100 at Week&nbsp;24 (60.1 % with Taltz vs 46.6% with ADA, p=0.001), which were the major secondary endpoints in the study.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Figure 2: Primary Endpoint (Simultaneous ACR&nbsp;50 &amp; PASI&nbsp;100) and Major Secondary Endpoints (ACR&nbsp;50; PASI&nbsp;100) Response Rates Week&nbsp;0&nbsp;&ndash;&nbsp;24 [ITT population, NRI]**</strong> <strong><!--[if gte vml 1]><v:shape id="Picture_x0020_16"
 o:spid="_x0000_i1026" type="#_x0000_t75" style='width:453.5pt;height:296.5pt;
 visibility:visible'>
 <v:imagedata src="file:///C:/Users/L011405/AppData/Local/Temp/msohtmlclip1/01/clip_image003.jpg"
  o:title=""/>
</v:shape><![endif]--><img width="605" height="395" alt="" src="file:///C:/Users/L011405/AppData/Local/Temp/msohtmlclip1/01/clip_image004.jpg" /></strong></p><p dir="ltr"><em>** Taltz 160&nbsp;mg Week&nbsp;0, then 80&nbsp;mg every 2&nbsp;weeks to Week&nbsp;12 and every 4&nbsp;weeks thereafter for patients with moderate to severe plaque psoriasis or 160&nbsp;mg Week&nbsp;0, then 80&nbsp;mg every 4&nbsp;week for other patients, ADA 80&nbsp;mg Week&nbsp;0, then 40&nbsp;mg every 2&nbsp;weeks from Week&nbsp;1 for patients with moderate to severe plaque psoriasis or 40&nbsp;mg Week&nbsp;0, then 40&nbsp;mg every 2&nbsp;weeks for other patients.</em></p><p dir="ltr"><em>Significance level only provided for endpoint that was pre-defined and multiplicity tested.</em></p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Other Health-Related Outcomes</em></p><p dir="ltr">General health status was assessed by the Short Form health survey (SF-36). At Week 12 in PsA1 and PsA2, patients treated with TALTZ showed greater improvement from baseline in the SF-36 physical component summary (PCS) score compared to patients treated with placebo but this improvement was not consistent in both studies for the SF-36 mental component summary (MCS) score. At Week 12, there was consistent evidence of effect in the physical-functioning, role-physical, bodily-pain, and general health domains but not in the social-functioning, role-emotional, vitality, and mental health domains.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Ankylosing Spondylitis</p><p dir="ltr">The safety and efficacy of TALTZ were assessed in 567 patients, in 2 randomized, double-blind, placebo-controlled studies (AS1 and AS2) in adult patients, age 18 years and older with active ankylosing spondylitis. Patients had active disease as defined by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) &ge;4 despite non-steroidal anti-inflammatory drug (NSAID), corticosteroid, or disease modifying anti-rheumatic drug (DMARD) therapy. At baseline, patients had symptoms of AS for an average of 17 years across both studies. At baseline, approximately 32% of the patients were on a concomitant cDMARD. In AS2, all patients discontinued previous treatment with 1 or 2 TNF inhibitors due to either inadequate response or intolerance.</p><p dir="ltr">AS1 Study (NCT&nbsp;02696785) evaluated 341 biologic-naive patients, who were treated with either TALTZ 80&nbsp;mg or 160&nbsp;mg at Week&nbsp;0 followed by 80&nbsp;mg every 2&nbsp;weeks (Q2W) or 4&nbsp;weeks (Q4W), adalimumab 40&nbsp;mg every 2&nbsp;weeks, or with placebo. Patients receiving placebo were re-randomized at Week 16 to receive TALTZ (160&nbsp;mg starting dose, followed by 80&nbsp;mg Q2W or Q4W). Patients receiving adalimumab were re-randomized at Week 16 to receive TALTZ (80&nbsp;mg Q2W or Q4W). AS2 Study (NCT&nbsp;02696798) evaluated 316 TNF-inhibitor experienced patients (90% were inadequate responders and 10% were intolerant to TNF inhibitors). All patients were treated with TALTZ 80 or 160&nbsp;mg at Week 0 followed by 80&nbsp;mg Q2W or Q4W, or with placebo. Patients receiving placebo were re-randomized at Week 16 to receive TALTZ (160&nbsp;mg initial dose, followed by 80&nbsp;mg Q2W or Q4W). The primary endpoint in both studies was the percentage of patients achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) response at Week&nbsp;16.</p><p dir="ltr"><u>Clinical Response</u></p><p dir="ltr">In both studies, patients treated with TALTZ 80&nbsp;mg Q4W demonstrated greater improvements in ASAS40 and ASAS20 responses compared to placebo at Week 16 (Table 7). Responses were seen regardless of concomitant therapies. In AS2, responses were seen regardless of prior TNF-inhibitor exposure.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Table 7: ASAS20 and ASAS40 Responses at Week 16, NRI<sup>a,b</sup></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>AS1 &ndash; biologic-naive</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>AS2 &ndash; TNF-inhibitor experienced</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>TALTZ</strong></p><p><strong>80&nbsp;mg</strong></p><p><strong>Q4W<sup>c</sup></strong></p><p><strong>(N=</strong><strong>81</strong><strong>)</strong></p></td><td><p><strong>Placebo (N=</strong><strong>87</strong><strong>)</strong></p></td><td><p><strong>Difference from placebo (95% CI)</strong></p></td><td style="vertical-align:top"><p><strong>TALTZ</strong></p><p><strong>80&nbsp;mg</strong></p><p><strong>Q</strong><strong>4</strong><strong>W<sup>c</sup></strong></p><p><strong>(N=</strong><strong>114</strong><strong>)</strong></p></td><td><p><strong>Placebo (N=</strong><strong>104</strong><strong>)</strong></p></td><td><p><strong>Difference from placebo (95% CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p>ASAS20 response<sup>d</sup>, %</p></td><td style="vertical-align:top"><p>64</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>24 (9, 39)</p></td><td style="vertical-align:top"><p>48</p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>18 (6, 31)</p></td></tr><tr><td style="vertical-align:top"><p>ASAS40 response<sup>d,e</sup>, %</p></td><td style="vertical-align:top"><p>48</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>30 (16, 43)</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>13 (3, 23)</p></td></tr></tbody></table><p dir="ltr"><sup>a</sup>&nbsp;&nbsp;&nbsp; Abbreviations: N = number of patients in the intent-to-treat population; NRI = Non-responder Imputation.</p><p dir="ltr"><sup>b</sup>&nbsp;&nbsp;&nbsp; Patients with missing data were counted as non-responders.</p><p dir="ltr"><sup>c</sup>&nbsp;&nbsp;&nbsp; At Week 0, patients received 80&nbsp;mg or 160&nbsp;mg of TALTZ.</p><p dir="ltr"><sup>d</sup>&nbsp;&nbsp;&nbsp; An ASAS20 response is defined as a &ge;20% improvement and an absolute improvement from baseline of &ge;1 units (range 0 to 10) in &ge;3&nbsp;of 4 domains (Patient Global, Spinal Pain, Function, and Inflammation), and no worsening of &ge;20% and &ge;1 unit (range 0 to 10) in the remaining domain. An ASAS40 response is defined as a &ge;40% improvement and an absolute improvement from baseline of &ge;2 units in &ge;3 of 4 domains without any worsening in the remaining domain.</p><p dir="ltr"><sup>e</sup>&nbsp;&nbsp;&nbsp; Primary endpoint.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The percent of patients achieving ASAS40 response by visit in AS1 is shown in Figure 3.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Figure 3: ASAS40 Response through Week 16, NRI<sup>a</sup></p><p dir="ltr"><!--[if gte vml 1]><v:shape id="Picture_x0020_5" o:spid="_x0000_i1027"
 type="#_x0000_t75" style='width:393pt;height:267pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/L011405/AppData/Local/Temp/msohtmlclip1/01/clip_image005.jpg"
  o:title=""/>
</v:shape><![endif]--><img width="524" height="356" alt="" src="file:///C:/Users/L011405/AppData/Local/Temp/msohtmlclip1/01/clip_image006.jpg" /></p><p dir="ltr"><sup>a</sup>&nbsp;&nbsp;&nbsp; Patients with missing data were counted as non-responders.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The improvement in the main components of the ASAS40 response criteria and other measures of disease activity are shown in Table 8.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Table 8: ASAS Components and Other Measures of Disease Activity at Week 16<sup>a,b</sup></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:690px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>AS1 &ndash; biologic-naive</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>AS2 &ndash; TNF-inhibitor experienced</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>TALTZ 80&nbsp;mg</strong></p><p><strong>Q4W<sup>c</sup> (N=</strong><strong>81</strong><strong>)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>(N=</strong><strong>87</strong><strong>)</strong></p></td><td style="vertical-align:top"><p><strong>TALTZ 80&nbsp;mg</strong></p><p><strong>Q</strong><strong>4</strong><strong>W<sup>c</sup> (N=</strong><strong>114</strong><strong>)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>(N=</strong><strong>104</strong><strong>)</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>ASAS Components</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>Patient Global Assessment (0-10)</p></td></tr><tr><td style="vertical-align:top"><p>Baseline</p></td><td style="vertical-align:top"><p>6.9</p></td><td style="vertical-align:top"><p>7.1</p></td><td style="vertical-align:top"><p>8.0</p></td><td style="vertical-align:top"><p>7.8</p></td></tr><tr><td style="vertical-align:top"><p>Mean Change from Baseline</p></td><td style="vertical-align:top"><p>-2.5</p></td><td style="vertical-align:top"><p>-1.4</p></td><td style="vertical-align:top"><p>-2.4</p></td><td style="vertical-align:top"><p>-0.7</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>Total Spinal Pain (0-10)</p></td></tr><tr><td style="vertical-align:top"><p>Baseline</p></td><td style="vertical-align:top"><p>7.2</p></td><td style="vertical-align:top"><p>7.4</p></td><td style="vertical-align:top"><p>7.9</p></td><td style="vertical-align:top"><p>7.8</p></td></tr><tr><td style="vertical-align:top"><p>Mean Change from Baseline</p></td><td style="vertical-align:top"><p>-3.2</p></td><td style="vertical-align:top"><p>-1.7</p></td><td style="vertical-align:top"><p>-2.4</p></td><td style="vertical-align:top"><p>-1.0</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>BASFI (0-10)</p></td></tr><tr><td style="vertical-align:top"><p>Baseline</p></td><td style="vertical-align:top"><p>6.1</p></td><td style="vertical-align:top"><p>6.4</p></td><td style="vertical-align:top"><p>7.4</p></td><td style="vertical-align:top"><p>7.0</p></td></tr><tr><td style="vertical-align:top"><p>Mean Change from Baseline</p></td><td style="vertical-align:top"><p>-2.4</p></td><td style="vertical-align:top"><p>-1.2</p></td><td style="vertical-align:top"><p>-1.7</p></td><td style="vertical-align:top"><p>-0.6</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>Inflammation (0-10)<sup>d</sup></p></td></tr><tr><td style="vertical-align:top"><p>Baseline</p></td><td style="vertical-align:top"><p>6.5</p></td><td style="vertical-align:top"><p>6.8</p></td><td style="vertical-align:top"><p>7.2</p></td><td style="vertical-align:top"><p>7.2</p></td></tr><tr><td style="vertical-align:top"><p>Mean Change from Baseline</p></td><td style="vertical-align:top"><p>-3.2</p></td><td style="vertical-align:top"><p>-1.3</p></td><td style="vertical-align:top"><p>-2.4</p></td><td style="vertical-align:top"><p>-0.7</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Other Measures of Disease Activity</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>BASDAI Score</p></td></tr><tr><td style="vertical-align:top"><p>Baseline</p></td><td style="vertical-align:top"><p>6.8</p></td><td style="vertical-align:top"><p>6.8</p></td><td style="vertical-align:top"><p>7.5</p></td><td style="vertical-align:top"><p>7.3</p></td></tr><tr><td style="vertical-align:top"><p>Mean Change from Baseline</p></td><td style="vertical-align:top"><p>-2.9</p></td><td style="vertical-align:top"><p>-1.4</p></td><td style="vertical-align:top"><p>-2.2</p></td><td style="vertical-align:top"><p>-0.9</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>BASMI</p></td></tr><tr><td style="vertical-align:top"><p>Baseline</p></td><td style="vertical-align:top"><p>3.9</p></td><td style="vertical-align:top"><p>4.5</p></td><td style="vertical-align:top"><p>4.7</p></td><td style="vertical-align:top"><p>4.9</p></td></tr><tr><td style="vertical-align:top"><p>Mean Change from Baseline</p></td><td style="vertical-align:top"><p>-0.5</p></td><td style="vertical-align:top"><p>-0.1</p></td><td style="vertical-align:top"><p>-0.3</p></td><td style="vertical-align:top"><p>-0.0</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>hsCRP (mg/L)</p></td></tr><tr><td style="vertical-align:top"><p>Baseline</p></td><td style="vertical-align:top"><p>12.2</p></td><td style="vertical-align:top"><p>16.0</p></td><td style="vertical-align:top"><p>20.2</p></td><td style="vertical-align:top"><p>16.0</p></td></tr><tr><td style="vertical-align:top"><p>Mean Change from Baseline</p></td><td style="vertical-align:top"><p>-5.2</p></td><td style="vertical-align:top"><p>1.4</p></td><td style="vertical-align:top"><p>-11.1</p></td><td style="vertical-align:top"><p>9.7</p></td></tr></tbody></table><p dir="ltr"><sup>a</sup>&nbsp;&nbsp;&nbsp; Abbreviations: ASDAS = Ankylosing Spondylitis Disease Activity Score; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; BASFI = Bath Ankylosing Spondylitis Functional Index; BASMI = Bath Ankylosing Spondylitis Metrology Index; hsCRP = High sensitivity C-reactive protein.</p><p dir="ltr"><sup>b</sup>&nbsp;&nbsp;&nbsp; Mean changes are least-squares mean changes from baseline at Week 16.</p><p dir="ltr"><sup>c</sup>&nbsp;&nbsp;&nbsp; At Week 0, patients received 80 or 160&nbsp;mg of TALTZ.</p><p dir="ltr"><sup>d</sup>&nbsp;&nbsp;&nbsp; Inflammation is the mean of patient-reported stiffness self-assessments (questions 5 and 6) in BASDAI.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Health-Related Outcomes</em></p><p dir="ltr">General health status and quality of life was assessed by the Short Form health survey (SF-36). At Week 16, in AS1 and AS2, compared to placebo, patients treated with TALTZ showed greater improvement from baseline in the SF-36 physical component summary (PCS) score and the physical functioning, role physical, bodily pain, vitality, and general health domains, with no consistent improvements in the mental component summary (MCS), social functioning, role emotional, and mental health domains.</p><p dir="ltr">Non-radiographic Axial Spondyloarthritis</p><p dir="ltr">The efficacy and safety of TALTZ were assessed in a randomized, double-blind, 52-week placebo-controlled study (nr-axSpA1) (NCT&nbsp;02757352) in patients &ge;18&nbsp;years of age with active axial spondyloarthritis for at least 3&nbsp;months. Patients must have had objective signs of inflammation indicated by elevated C-reactive protein (CRP) (defined as greater than 5&nbsp;mg/L), and/or sacroiliitis on magnetic resonance imaging (MRI), and no definitive radiographic evidence of structural damage on sacroiliac joints. Patients had active disease as defined by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) &ge;4, and spinal pain &ge;4 on a 0 to 10 Numerical Rating Scale (NRS). Patients must have been intolerant to or had an inadequate response to at least two NSAIDs. Patients were treated with either placebo or TALTZ 80&nbsp;mg or 160&nbsp;mg at Week 0, followed by either 80&nbsp;mg every 2&nbsp;weeks (Q2W) or 80&nbsp;mg every 4&nbsp;weeks (Q4W). Initiation and/or dose adjustment of concomitant medications (NSAIDs, cDMARDs, corticosteroids, analgesics) were permitted starting at Week 16. Patients were allowed to transition to use of open-label TALTZ 80&nbsp;mg Q2W starting at Week 16 up to Week 44 at the discretion of the investigator.</p><p dir="ltr">At baseline, patients had symptoms of nr-axSpA for an average of 11&nbsp;years. Approximately 39% of the patients were on a concomitant cDMARD.</p><p dir="ltr">The primary endpoint was the percentage of patients achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) response at Week 52. The ASAS40 response was also evaluated at Week 16 as a major secondary endpoint.</p><p dir="ltr"><u>Clinical Response</u></p><p dir="ltr">At both Weeks 16 and 52, a greater proportion of patients treated with TALTZ 80&nbsp;mg Q4W had ASAS40 response compared to patients treated with placebo (Table 10). The components of ASAS response criteria and CRP are shown in Table 9.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Table 9: ASAS40 Responses at Week 16 and Week 52, NRI<sup>a,b</sup></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>Week 16</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Week 52</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>TALTZ</strong></p><p><strong>80&nbsp;mg</strong></p><p><strong>Q4W<sup>c,d</sup></strong></p><p><strong>(N=96)</strong></p></td><td><p><strong>Placebo (N=105)</strong></p></td><td><p><strong>Difference from placebo (95% CI)</strong></p></td><td style="vertical-align:top"><p><strong>TALTZ</strong></p><p><strong>80&nbsp;mg</strong></p><p><strong>Q4W<sup>c,d</sup></strong></p><p><strong>(N=96)</strong></p></td><td><p><strong>Placebo (N=105)</strong></p></td><td><p><strong>Difference from placebo (95% CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>ASAS40 response<sup>e</sup>, %</strong></p></td><td style="vertical-align:top"><p>35.4</p></td><td style="vertical-align:top"><p>19.0</p></td><td style="vertical-align:top"><p>16.4 (4.2, 28.5)</p></td><td style="vertical-align:top"><p>30.2</p></td><td style="vertical-align:top"><p>13.3</p></td><td style="vertical-align:top"><p>16.9 (5.6, 28.1)</p></td></tr></tbody></table><p dir="ltr"><sup>a</sup>&nbsp;&nbsp;&nbsp; Abbreviations: N = number of patients in the intent-to-treat population; NRI = Non-responder Imputation.</p><p dir="ltr"><sup>b</sup>&nbsp;&nbsp;&nbsp; Patients who initiated open-label TALTZ 80&nbsp;mg Q2W, or discontinued initially randomized treatment and remained in the study, or were missing Week 16 or Week 52 data were counted as non-responders.</p><p dir="ltr"><sup>c</sup>&nbsp;&nbsp;&nbsp; Starting at Week 16 and up to Week 44, patients who were determined as inadequate responders by investigators were given the option to make changes in their background therapy and/or transition to open label TALTZ 80&nbsp;mg Q2W.</p><p dir="ltr"><sup>d</sup>&nbsp;&nbsp;&nbsp; At Week 0, patients received 80&nbsp;mg or 160&nbsp;mg of TALTZ.</p><p dir="ltr"><sup>e</sup>&nbsp;&nbsp;&nbsp; An ASAS40 response is defined as a &ge;40% improvement and an absolute improvement from baseline of &ge;2 units in &ge;3 of 4 domains without any worsening in the remaining domain.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The improvement in the main components of the ASAS40 response criteria and other measures of disease activity at Week 16 are shown in Table 10.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Table 10: ASAS Components and Other Measures of Disease Activity at Week 16<sup>a</sup></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:684px"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>TALTZ 80&nbsp;mg</strong></p><p><strong>Q4W<sup>b</sup> (N=96)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>(N=105)</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>ASAS Components</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Patient Global Assessment (0-10)</p></td></tr><tr><td style="vertical-align:top"><p>Baseline</p></td><td style="vertical-align:top"><p>7.1</p></td><td style="vertical-align:top"><p>7.4</p></td></tr><tr><td style="vertical-align:top"><p>Mean Change from Baseline<sup>c</sup></p></td><td style="vertical-align:top"><p>-2.3</p></td><td style="vertical-align:top"><p>-1.3</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Total Spinal Pain (0-10)</p></td></tr><tr><td style="vertical-align:top"><p>Baseline</p></td><td style="vertical-align:top"><p>7.3</p></td><td style="vertical-align:top"><p>7.4</p></td></tr><tr><td style="vertical-align:top"><p>Mean Change from Baseline<sup>c</sup></p></td><td style="vertical-align:top"><p>-2.4</p></td><td style="vertical-align:top"><p>-1.5</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>BASFI (0-10)</p></td></tr><tr><td style="vertical-align:top"><p>Baseline</p></td><td style="vertical-align:top"><p>6.4</p></td><td style="vertical-align:top"><p>6.7</p></td></tr><tr><td style="vertical-align:top"><p>Mean Change from Baseline<sup>c</sup></p></td><td style="vertical-align:top"><p>-2.0</p></td><td style="vertical-align:top"><p>-1.3</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Inflammation (0-10)<sup>d</sup></p></td></tr><tr><td style="vertical-align:top"><p>Baseline</p></td><td style="vertical-align:top"><p>6.8</p></td><td style="vertical-align:top"><p>7.0</p></td></tr><tr><td style="vertical-align:top"><p>Mean Change from Baseline<sup>c</sup></p></td><td style="vertical-align:top"><p>-2.5</p></td><td style="vertical-align:top"><p>-1.5</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Other Measures of Disease Activity</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>BASDAI Score (0-10)</p></td></tr><tr><td style="vertical-align:top"><p>Baseline</p></td><td style="vertical-align:top"><p>7.0</p></td><td style="vertical-align:top"><p>7.2</p></td></tr><tr><td style="vertical-align:top"><p>Mean Change from Baseline<sup>c</sup></p></td><td style="vertical-align:top"><p>-2.2</p></td><td style="vertical-align:top"><p>-1.5</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>BASMI (0-10)</p></td></tr><tr><td style="vertical-align:top"><p>Baseline</p></td><td style="vertical-align:top"><p>3.2</p></td><td style="vertical-align:top"><p>3.2</p></td></tr><tr><td style="vertical-align:top"><p>Mean Change from Baseline<sup>c</sup></p></td><td style="vertical-align:top"><p>-0.4</p></td><td style="vertical-align:top"><p>-0.2</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>hsCRP (mg/L)</p></td></tr><tr><td style="vertical-align:top"><p>Baseline</p></td><td style="vertical-align:top"><p>12.4</p></td><td style="vertical-align:top"><p>14.3</p></td></tr><tr><td style="vertical-align:top"><p>Mean Change from Baseline<sup>c</sup></p></td><td style="vertical-align:top"><p>-8.0</p></td><td style="vertical-align:top"><p>-3.0</p></td></tr></tbody></table><p dir="ltr"><sup>a</sup>&nbsp;&nbsp;&nbsp; Abbreviations: BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; BASFI = Bath Ankylosing Spondylitis Functional Index; BASMI = Bath Ankylosing Spondylitis Metrology Index; hsCRP = High sensitivity C-reactive protein; NRI = Non-responder Imputation.</p><p dir="ltr"><sup>b</sup>&nbsp;&nbsp;&nbsp; At Week 0, patients received 80 or 160&nbsp;mg of TALTZ.</p><p dir="ltr"><sup>c</sup>&nbsp;&nbsp;&nbsp; Mean changes are least-squares mean changes from baseline at Week 16 using a mixed model for repeated measures adjusting for treatment group, screening MRI/CRP classification, visit, continuous baseline, interaction of visit with treatment, interaction of continuous baseline with visit.</p><p dir="ltr"><sup>d</sup>&nbsp;&nbsp;&nbsp; Inflammation is the mean of patient-reported stiffness self-assessments (questions 5 and 6) in BASDAI questionnaire.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The percent of patients achieving ASAS40 responses by visit is shown in Figure 4.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Figure 4: ASAS40 Responses through Week 16, NRI<sup>a</sup></p><p dir="ltr"><!--[if gte vml 1]><v:shape id="Picture_x0020_2" o:spid="_x0000_i1028"
 type="#_x0000_t75" style='width:386pt;height:286.5pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/L011405/AppData/Local/Temp/msohtmlclip1/01/clip_image007.jpg"
  o:title=""/>
</v:shape><![endif]--><img width="515" height="382" alt="" src="file:///C:/Users/L011405/AppData/Local/Temp/msohtmlclip1/01/clip_image008.jpg" /></p><p dir="ltr"><sup>a</sup>&nbsp;&nbsp;&nbsp; Patients with missing data were counted as non-responders.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Health-Related Outcomes</em></p><p dir="ltr">General health status and quality of life was assessed by the Short Form health survey (SF-36). At Week 16, compared to placebo, nr-axSpA patients treated with TALTZ 80&nbsp;mg Q4W showed greater improvement from baseline in the SF-36 physical component summary (PCS) score and physical functioning, bodily pain, vitality, and social functioning domains, with no consistent improvements in the mental component summary (MCS), role physical, general health, role emotional, and mental health domains.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr">The pharmacokinetic (PK) properties of ixekizumab were similar across the adult plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis indications.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Absorption</u></p><p dir="ltr">Following a single subcutaneous dose of 160&nbsp;mg in subjects with plaque psoriasis, ixekizumab reached peak mean (&plusmn;SD) serum concentrations (C<sub>max</sub>) of 16.2 &plusmn;6.6 mcg/mL by approximately 4 days post dose.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Steady-state concentrations were achieved by Week 8 following the 160&nbsp;mg starting dose and 80&nbsp;mg every 2&nbsp;weeks dosing regimen; the mean &plusmn;SD steady-state trough concentration was 9.3 &plusmn;5.3&nbsp;mcg/mL. Steady-state concentrations were achieved approximately 10&nbsp;weeks after switching from the 80&nbsp;mg every 2&nbsp;weeks dosing regimen to the 80 mg every 4 weeks dosing regimen at Week 12. The mean &plusmn;SD steady-state trough concentration was 3.5 &plusmn;2.5&nbsp;mcg/mL.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In studies of subjects with plaque psoriasis, ixekizumab bioavailability ranged from 60% to 81% following subcutaneous injection. Administration of ixekizumab via injection in the thigh achieved a higher bioavailability relative to that achieved using other injection sites including the arm and abdomen.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Distribution</u></p><p dir="ltr">The mean (geometric CV%) volume of distribution at steady-state was 7.11&nbsp;L (29%) in subjects with plaque psoriasis.</p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><u>Elimination</u></p><p dir="ltr">The metabolic pathway of ixekizumab has not been characterized. As a humanized IgG4 monoclonal antibody ixekizumab is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The mean systemic clearance was 0.39&nbsp;L/day (37%) and the mean (geometric CV%) half-life was 13 days (40%) in subjects with plaque psoriasis.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Weight</u></p><p dir="ltr">Ixekizumab clearance and volume of distribution increase as body weight increases.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Dose Linearity</u></p><p dir="ltr">Ixekizumab exhibited dose-proportional pharmacokinetics in subjects with plaque psoriasis over a dose range from 5&nbsp;mg (not the recommended dose) to 160&nbsp;mg following subcutaneous administration.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Specific Populations</u></p><p dir="ltr"><em>Pediatric Use</em></p><p dir="ltr">The safety and effectiveness of TALTZ have been established in pediatric subjects aged 6 years to less than 18 years with moderate-to-severe plaque psoriasis. The safety and effectiveness of TALTZ in other pediatric indications and for pediatric subjects less than 6 years of age have not been established.</p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr"><em>Age: Geriatric Population</em></p><p dir="ltr">Population pharmacokinetic analysis indicated that age did not significantly influence the clearance of ixekizumab in adult subjects with plaque psoriasis. Subjects who are 65 years or older had a similar ixekizumab clearance as compared to subjects less than 65 years old.</p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr">Of the 4204 adult psoriasis subjects exposed to TALTZ, a total of 301 were 65 years or older, and 36 subjects were 75 years or older. Although no differences in safety or efficacy were observed between older and younger subjects, the number of subjects aged 65 and over is not sufficient to determine whether they respond differently from younger subjects.</p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr"><em>Pediatric Population</em></p><p dir="ltr">Pediatric psoriasis subjects (6 to less than 18 years of age) were administered ixekizumab at the recommended pediatric dosing regimen for 12 weeks. Subjects weighing &gt;50&nbsp;kg had a mean &plusmn;SD steady-state trough concentration of 3.8 &plusmn;2.2&nbsp;mcg/mL.</p><p dir="ltr"><em>&nbsp;</em></p><p><em>Renal or Hepatic Impairment</em></p><p>Specific clinical pharmacology studies to evaluate the effects of renal impairment and</p><p>hepatic impairment on the PK of ixekizumab have not been conducted.</p><p>&nbsp;</p><p dir="ltr"><u>Drug Interaction Studies</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Population PK data analyses indicated that the clearance of ixekizumab was not impacted by concomitant administration of methotrexate, or by prior exposure to methotrexate or adalimumab in patients with psoriatic arthritis.</p><p dir="ltr">Population PK data analyses indicated that the clearance of ixekizumab was not impacted by concomitant administration of oral corticosteroids, NSAIDs, or cDMARDs (sulfasalazine and methotrexate) in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis.</p><p dir="ltr"><em>Cytochrome P450 Substrates</em></p><p dir="ltr">No clinically significant changes in exposure of caffeine (CYP1A2 substrate), warfarin (CYP2C9 substrate), omeprazole (CYP2C19 substrate) or midazolam (CYP3A substrate) were observed in subjects with plaque psoriasis when used concomitantly with a single 160&nbsp;mg dose of ixekizumab, or multiple doses of 80&nbsp;mg every 2&nbsp;weeks. The potential effect of ixekizumab on the CYP2D6 activity cannot be ruled out due to high variability in exposure (approximately &plusmn;2-fold) of dextromethorphan and its CYP2D6 metabolite dextrorphan in psoriasis subjects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Carcinogenesis, Mutagenesis, Impairment of Fertility</p><p dir="ltr">Animal studies have not been conducted to evaluate the carcinogenic or mutagenic potential of TALTZ. Moreover published literature is mixed on potential effects on malignancy risk due to the inhibition of IL-17A activity, the pharmacological action of TALTZ. Some published literature suggests that IL-17A directly promotes cancer cell invasion, suggesting a potential beneficial effect by TALTZ, whereas other reports indicate IL-17A promotes T-cell mediated tumor rejection, suggesting a potential adverse effect by TALTZ. However, neutralization of IL-17A with TALTZ has not been studied in these models. Depletion of IL-17A with a neutralizing antibody inhibited tumor development in mice, suggesting a potential beneficial effect by TALTZ. The relevance of experimental findings in mouse models for malignancy risk in humans is unknown.</p><p dir="ltr">&nbsp;</p><p dir="ltr">No effects on fertility parameters such as reproductive organs, menstrual cycle length, or sperm analysis were observed in sexually mature cynomolgus monkeys that were administered ixekizumab for 13 weeks at a subcutaneous dose of 50&nbsp;mg/kg/week (19 times the MRHD on a mg/kg basis). The monkeys were not mated to evaluate fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sucrose&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;80mg/mL</p><p>Polysorbate 80&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;..0.30mg/mL</p><p>Water for Injection&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;.q.s to 1.0 mL</p><p>Sodium hydroxide may have been added to adjust pH</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No object</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>How Supplied</strong></p><p dir="ltr">TALTZ injection is a sterile, preservative free, clear and colorless to slightly yellow solution available in a single-dose prefilled autoinjector to deliver 80&nbsp;mg ixekizumab.</p><p dir="ltr">TALTZ is supplied as:</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p><strong>Autoinjector</strong></p></td><td style="vertical-align:top"><p><strong>Pack Size</strong></p></td></tr><tr><td style="vertical-align:top"><p>80&nbsp;mg single-dose</p></td><td style="vertical-align:top"><p>Carton of 1</p></td></tr><tr><td style="vertical-align:top"><p>80&nbsp;mg single-dose</p></td><td style="vertical-align:top"><p>Carton of 2</p></td></tr><tr><td style="vertical-align:top"><p>80&nbsp;mg single-dose</p></td><td style="vertical-align:top"><p>Carton of 3</p></td></tr></tbody></table><p dir="ltr">Not all pack sizes are marketed.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>Storage and Handling</strong></p><p dir="ltr">TALTZ is sterile and preservative-free. Discard any unused portion.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp; TALTZ must be protected from light until use.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp; Store refrigerated at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F).</p><p dir="ltr">&bull;&nbsp;&nbsp; If needed, patients/caregivers may store TALTZ at room temperature up to 30&deg;C (86&deg;F) for up to 5 days in the original carton to protect from light. Once TALTZ has been stored at room temperature, do not return to the refrigerator and discard, if unused, within 5 days.</p><p dir="ltr">&bull;&nbsp;&nbsp; Record the date when TALTZ is first removed from the refrigerator in the spaces provided on the carton.</p><p dir="ltr">&bull;&nbsp;&nbsp; For the 2 or 3 autoinjector pack, remove a single autoinjector at a time leaving the remaining autoinjector(s) in the original carton in the refrigerator. Ensure the unrefrigerated TALTZ is protected from light.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp; Do not freeze. Do not use TALTZ if it has been frozen.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp; Do not shake.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp; Discard the TALTZ single-dose autoinjector or syringe after use in a puncture-resistant container.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp; Not made with natural rubber latex.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>Patient Counseling Information</strong></p><p dir="ltr">Advise the patient and/or caregiver to read the FDA-approved patient labeling <em>(Medication Guide and Instructions for Use)</em> before the patient starts using TALTZ, and each time the prescription is renewed, as there may be new information they need to know.</p><p dir="ltr"><u>Instructions on Self-Administration</u>: Provide guidance to patients and caregivers on proper subcutaneous injection technique, including aseptic technique, and how to use the autoinjector correctly <em>[see Instructions for Use]</em>.</p><p dir="ltr"><u>Infection</u>: Inform patients that TALTZ may lower the ability of their immune system to fight infections, and that serious infections, including opportunistic infections, may occur with the use of TALTZ. Instruct patients of the importance of communicating any history of infections to the healthcare provider, and contacting their healthcare provider if they develop any symptoms of infection <em>[see Special Warnings and Precautions for Use (4.4)]</em>.</p><p dir="ltr"><u>Allergic Reactions</u>: Advise patients to seek immediate medical attention if they experience any symptoms of serious hypersensitivity reactions <em>[see Special Warnings and Precautions for Use (4.4)]</em>.</p><p><u>Eczematous Eruptions:</u> Inform patients that skin reactions resembling eczema may occur with the use of TALTZ. Instruct patients to seek medical advice if they develop signs or symptoms of eczema <em>[see </em><em>Special Warnings and Precautions for Use (4.4)].</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">The primary container closure system for ixekizumab injection is a Type I clear glass, 1 mL-long</p><p dir="ltr">glass syringe barrel with small round flange, 27G special thin wall x 1/2&quot; staked needle, and</p><p dir="ltr">closed with a barrier film laminated elastomeric plunger and rigid needle shield.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Eli Lilly and Company, Building 105, INDIANAPOLIS, USA
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                August 2024
Version 9


            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>